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Abstract
Katz, Aron Matthew Ph.D. The University of Memphis. August 2014. Testing body
vigilance as a precipitating factor in the cognitive behavioral model of medically
unexplained illness. Major Professor: Douglas Strohmer

Chronic illness affects nearly one in two Americans affected (CDC, 2009), often
leading to psychological distress (Bohlmeijer, Prenger, Taal, & Cuijpers, 2010),
including a rate of depression approximately 50% higher than the rate in peers without
medical illness (Patten, 2001). Likewise, quality of life for those with chronic illnesses is
lower than quality of life among healthy peers, measured by greater persistence of
psychological distress, higher functional impairment, and medical services utilization
(Aiarzaguena, Grandes, Salazar, Gaminde, & Sánchez, 2008; Feder et al., 2001). Despite
continued medical advances, a significant portion of illness, pain and discomfort remains
medically unexplained (Nettleton, Watt, O’Malley, & Duffey, 2005), creating challenges
not only for those who experience illness distress, but for health care providers as well
(Kroenke, 2000; Raine et al., 2002). Medically unexplained symptoms (MUS), defined
as sets of symptoms that physical pathology does not adequately explain (Swanson,
Hamilton, & Feldman, 2010), are both commonplace and problematic to health care
providers (Kroenke, 2000; Swanson et al., 2010). Deary, Chalder, and Sharpe’s (2007)
cognitive behavioral model of medically unexplained symptoms describes the process by
which correlates of illness-related distress prime, trigger and perpetuate the experience of
aversive symptoms even in the absence of direct physiological causes. Although , in
recent years, the cognitive behavioral model of MUS has garnered increasing empirical
support for predisposing and perpetuating variables, no published articles to date have
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investigated the role of precipitating factors in the context of this model, leaving a critical
component of the theory unexamined.
This study used a sample population of adults with Inflammatory Bowel Disease
to test the role of body vigilance as a precipitating factor in the CBT model of MUS.
Results indicated that the inclusion of body vigilance significantly improved explained
variance. Although patterns of correlation between personality variables, illness
cognitions, and health related quality of life were similar among persons with IBD and
other diseases used to test the model, among adults with IBD, no personality variables
explained significant variance in health-related quality of life. The implications of how
these results may impact further research in MUS and chronic illness are provided.
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Chapter 1
Introduction
Over the past century, improvements in preventive care and treatment of medical
illness have led to the emergence of growing population living with chronic illness
(Cohen, McChargue, & Collins, 2003; Fennell, 2003). The Center for Disease Control
estimates that nearly one in two Americans or approximately 133 million people have a
chronic health condition (CDC, 2009), and the numbers are rising. The U.S. Department
of Health and Human Services projects that, by the year 2020, approximately 157 million
Americans will be living with some sort of chronic disease (Wu & Green, 2000).
Patients with chronic somatic diseases experience psychological distress at higher
rates than their healthy peers (Bohlmeijer et al., 2010) including a rate of depression
approximately 50% higher than peers without medical illness (Patten, 2001). Likewise,
quality of life for those with chronic illnesses is lower than healthy peers, measured by
greater persistence of psychological distress, higher functional impairment, and medical
services utilization (Aiarzaguena et al., 2008; Feder et al., 2001).
Despite medical advances, a significant portion of illness, pain, and discomfort
remains medically unexplained (Nettleton et al., 2005). Medically unexplained
symptoms (MUS), defined as sets of symptoms that physical pathology does not
adequately explain (Swanson et al., 2010), are both commonplace and problematic to
health care providers (Kroenke, 2000; Swanson et al., 2010). In the U.K., over half of all
primary care mental health consultations are for medically unexplained symptoms
(Hague, 2005). In the U.S. between 15% (Aiarzaguena et al., 2008) and 20% (Hartz et
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al., 2000) of patients presenting to general practitioners have somatic symptoms with no
clear physiological basis.
MUS are particularly challenging to treat for health care providers (Kroenke,
2000; Raine et al., 2002). Patients with MUS use more health care services and often
receive more tests and treatments at greater cost than may be necessary (Aiarzaguena et
al., 2008). They also experience significant psychological distress and poorer quality of
life (Koch et al., 2007). The impact of MUS extends beyond patient and provider, as it
accounts for a significant proportion of disability in the workforce (Kroenke et al., 1994;
Reid, Wessely, Crayford, & Hotopf, 2001).
Given the high instance rate, the impact on subjective quality of life and the
challenges in effective management, there is a clear need for a theoretical framework
from which to build empirically validated treatments for individuals with MUS (Deary et
al., 2007). Cognitive-behavioral therapy (CBT) is the therapeutic approach with the most
empirical support in the treatment of somatic symptoms including MUS (Burton, 2003;
Nezu, Nezu, & Lombardo, 2001; Sumathipala, 2007). In addition, there is considerable
support for a cognitive behavioral conceptual model for understanding the development
and maintenance of symptoms in the absence of direct physiological pathology (Deary et
al., 2007; Mai, 2004; Neimark, Caroff, & Stinnett, 2005). The cognitive behavioral
model of MUS (Figure 1) outlines the relationships between sets of factors believed to be
relevant in the development and maintenance of MUS. These factors are separated into
three categories of variables: predisposing factors influence likelihood of the symptom
first occurring, precipitating factors which influence the direct triggering of the symptom,
and perpetuating factors which are both effects and secondary causes of the symptom.
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Predisposing Factors
Precipitating Factors
Medically Unexplained
Symptoms
Perpetuating Factors

Figure 1. Relationship between categories of variables in the cognitive behavioral model of
medically unexplained symptoms. Adapted from “The cognitive behavioural model of
medically unexplained symptoms: a theoretical and empirical review,” by Deary, V.,
Chalder, T., & Sharpe, M. (2007). Clinical Psychology Review, 27, p. 9. Copyright 2007 by
Elsevier Ltd.

The model helps illustrate the dynamic relationship between correlates of illnessrelated distress that prime, trigger and perpetuate the experience of aversive symptoms
even in the absence of direct physiological causes. Although in recent years, the cognitive
behavioral model of MUS has garnered increasing empirical support for predisposing and
perpetuating variables, no published articles to date have examined the role of
precipitating factors in the context of this model, leaving a critical component of the
theory unexamined. Thus the purpose of the proposed research is to test the role of body
vigilance as a precipitating factor in the cognitive behavioral model of MUS.
Cognitive Behavioral Model of MUS
The most comprehensive application of cognitive behavioral therapy to the class
of disorders labeled MUS is found in Deary et al.’s (2007) cognitive behavioral model of
medically unexplained symptoms. The “CBT model of MUS” helps explain the selfperpetuating elements of MUS that make them particularly difficult to treat. Based on
Beck’s cognitive therapy (Beck, 1976), the cognitive behavioral theory of MUS
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distinguishes between predisposing, perpetuating and precipitating factors in the
development and maintenance of physical and emotional distress. The following section
will provide a brief review of the theoretical rationale and current support for the CBT
model of MUS.
Predisposing Factors. The CBT model of MUS defines predisposing factors as
variables which influence a person’s likelihood to experience illness-related distress.
Included among the predisposing factors are one’s genetics and personality traits which
may prime a person to experience medically unexplained symptoms.
Deary et al. note that although a genetic component to MUS is possible, and has
been demonstrated in select cases such as chronic fatigue and somatization (Farmer,
Scourfield, Martin, Cardno, & McGuffin, 1999; Hickie, Kirk, & Martin, 1999; Kendler,
Gardner, & Prescott, 2003), little is known about direct genetic links to MUS in general.
However, gender, a social construct analogous to genetically determined sex, has a
demonstrated association with MUS, with women reporting more frequent and more
severe somatic distress than men (De Gucht, Fischler, & Heiser, 2004; Feder et al., 2001;
Neimark et al., 2005; Wool & Barsky, 1994). The source of gender differences in
frequency and severity of MUS is unclear. It is plausible, for instance, that similar
internal experiences among males and females are differentially reported due to
differences in perceived social acceptability of reporting physical complaints. In addition
to gender, personality type, specifically trait neuroticism and alexithymia, is believed to
predispose people to MUS.
Neuroticism, defined as the tendency to experience negative, distressing emotions
and to possess associated behavioral and cognitive traits (Costa & McRae, 1987), is
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linked to heightened reactivity, and an increase in perception of negative life events
(Magnus, Diener, Fujita, & Pavot, 1993). Neuroticism is also associated with several
components of the cognitive-behavioral model that may contribute to symptom detection
and perpetuation of distress (Deary et al., 2007). Neuroticism is linked to autonomic
arousal and neurologically based sensitivity to punishment signals (Matthews &
Gilliland, 1999), thus changing the threshold for precipitation of distress. Watson and
Pennebaker (1989) suggested it be seen not just as a psychological trait but as a more
general predisposition to experience “somatopsychic distress.” In this sense, a direct
relationship between neuroticism and illness distress is possible. Higher neuroticism is
associated with increased levels of depression and poorer prognosis in a variety of MUS
(Deary et al., 2007). and is also associated with lower health-related quality of life in
MUS (Deary et al., 1997). It is correlated highly with harm-avoidance (Cloninger, 1987),
conditioning to noxious stimuli, and increased generalization of conditioned response
(Van den Bergh, Winters, Devriese, & Van Diest, 2002).
Another dimension of personality that has been hypothesized to play a role in the
development and persistence of MUS is alexithymia (De Gucht et al., 2004; Deary et al.,
1997). Literally meaning “no words for feelings,” alexithymia has three facets: difficulty
identifying and describing feelings, difficulty in distinguishing between feelings and
bodily sensations of emotional arousal, and the tendency to focus on the concrete details
of external events (Lesser, 1981; Nemia, Freyberger, & Sifnos, 1976; Taylor 1984).
Higher levels of alexithymia are associated with greater somatic distress, both among
patients receiving medical care and in nonclinical populations (Bailey & Henry, 2007;
Deary et al., 1997).
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The CBT model of MUS predicts that these predisposing factors lower the initial
threshold and raise the likelihood of the experience of distress. For instance, a person
who has a neurotic disposition and experiences high levels of negative affect might be
more apt to notice and to focus on painful or unpleasant sensations than a person whose
affect is neutral or predominantly positive. Similarly, difficulty identifying, describing
and distinguishing emotions and sensations could be anxiety provoking and unpleasant in
its own right (Dorrian, Dempster, & Adair, 2009). Leventhal, Nerenz, and Purse (1984)
theorized that ill individuals seek to label their condition, and may prematurely attribute
ambiguous sensations as related to their conditions, lowering their assessments of
functional independence. Both neuroticism and alexithymia fit in Deary’s
conceptualization of predisposing factors, which are intrinsic traits that influence the
likelihood of distress before any symptoms are perceived. In contrast, perpetuating
factors exert influence only after the symptoms surface. The following section will
describe the role of perpetuating factors in the CBT model of MUS.
Perpetuating Factors. The CBT model of MUS defines perpetuating factors as
variables which both result from and are a secondary cause of unexplained symptoms,
and function to prolong illness-related distress. Included in Deary et al.’s (2007)
conceptualization of perpetuating factors are beliefs, attitudes and responses to MUS,
which in this study will be collectively referred to as cognitive representations. In the
CBT model of MUS, cognitive representations resulting from chronic and unexplained
somatic symptoms can prolong the symptoms, and affect sensitivity to future MUS, this
perpetuating the cycle. This interaction perpetuates the cycle of MUS and illness-related
distress. In the present study, illness representations include beliefs about illness identity
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(the degree to which symptoms can be attributed to a specific diagnostic label), chronicity
(the belief that the illness will be long lasting rather than acute and passing), cyclical
nature (the belief that symptoms may alternate between periods of exacerbation and
remission), consequences (the belief in the severity of the condition), personal control
(the belief in one’s ability to control symptoms when they emerge), treatment control (the
belief that effective treatment can help to manage symptoms), illness coherence (the
belief in a coherent understanding of one’s condition), and emotional representation
(specific emotional responses to illness states.) A number of studies support illness
representations as a predictor of quality of life across a range of conditions, including
rheumatoid arthritis, COPD and psoriasis (Scharloo et al., 1998), asthma (Leventhal,
Diefenbach, & Leventhal, 1992), chronic fatigue syndrome (Heijmans & de Ridder,
1998), irritable bowel syndrome (Rutter & Rutter, 2002), and inflammatory bowel
disease (Dorrian et al., 2009).
Specific cognitive illness representations can be both indicators of and
contributors to somatic symptoms. For instance, a person who has lived with an intrusive
MUS for an extended period of time may, as a result of direct experience, hold beliefs
that his or her condition is disabling, unresponsive to medical treatment, poorly
understood and uncontrollable. These thoughts, resulting from experience would be
indicators of somatic distress. Additionally, they could contribute to distress and prime
the individual to perceive distress more readily than a person with different cognitive
representations. The cognitive behavioral model of MUS predicts that these cognitive
representations perpetuate MUS by influencing the sensitivity and thus lowering the
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threshold for symptom detection and precipitation of illness distress. The following
section will describe the role of precipitating factors in the CBT model of MUS.
Precipitating Factors. The final set of factors in the cognitive behavioral model
of MUS involves the triggering of the MUS, what Deary et al. (2007) call precipitating
factors. In the model, precipitants to MUS encompass any stressors that trigger MUS and
the start of the self-perpetuating cycle. A crucial component of the CBT model of MUS
is the idea that the threshold for triggering MUS can change through sensitization.
Sensitization refers to the tendency for prior experience of a stimulus to induce a
heightened reactivity to future stimuli (Deary et al., 2007). Rygh et al. (2005) have
shown that long term potentiation in humans can be induced in pain pathways by prior
experience of pain or noxious stimulation, which lowers the threshold for future
stimulation. Rygh et al. (2005) suggested that mechanisms such as vigilance and
attention, or the effects of anxiety, depression or stress, may dampen inhibition of these
pathways, lowering the threshold further in line with Melzak’s Gate Control Theory
(1968). This could lead to normally benign sensations being experienced as pain, leading
in turn to further sensitization and vigilance.
Such a relationship has been shown in patients with irritable bowel syndrome
(IBS), in which aversive IBS symptoms produced a fear response, leading to discomfort
intolerance, increased vigilance, perception, anxiety and again to IBS symptoms
(Keough, Timpano, Zawilinski, & Schmidt, 2011). Body vigilance was found to
correlate with symptom severity (r =.13; p < .01) (Keough et al., 2011). Although this
finding is compelling, the association was studied without other elements of the CBT
model of MUS. Without variables representing the complete model, it is impossible to
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determine whether the relationship between vigilance and distress is unique or if the
results may be due to overlapping constructs. To date, no study has examined body
vigilance in the context of the CBT model of MUS.
Self Maintaining Nature of CBT Model of MUS
The CBT model of MUS proposes a self-reinforcing process wherein known
correlates to illness-related distress also influence detection through sensitization, thus
leading to and maintaining MUS. Deary et al. (2007) describe this process as
“autopoeisis,” borrowing the concept from systems theory and cell biology in which the
components of the model, through their interaction, generate recursively the same
network of processes which produced them.
In this model, predisposing factors including genetic predisposition and
personality prime a person to heightened sensitivity, lower distress tolerance, and thus a
heightened experience of symptoms and related distress. In turn, distress has unique bidirectional relationships with perpetuating factors such as illness-related cognitions,
differential attention, and coping thoughts and behaviors, each of which could directly or
indirectly, through heightened sensitization, lead to greater distress in a positive feedback
loop.
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Chronic experience of somatic distress is believed to lead to increased attention
and sensitization, and thus to greater perception of somatic distress, a process that Barsky
and Wyshak called somatosensory amplification (Barsky & Wyshak, 1990). For
example, a person who has experienced persistent, chronic pain may anticipate future
pain, and increase attention paid to bodily sensations, effectively lowering the threshold
to future detection. Brown expanded on this idea by proposing a multi-component model
for MUS, which suggests that “rogue representations” in the cognitive system create
memory traces functionally similar to those generated during symptom experience, and
reinforce selective attention to physical sensations, disease-confirming beliefs and
negative affect (Brown, 2004). In Deary’s (2007) cognitive behavioral model of MUS,
sensitization to medically unexplained symptoms over time may influence the reactivity
of an individual to distress. This relationship is illustrated in Figure 2.

Predisposing Factors:
Gender, Trait Neuroticism, Alexithymia
Precipitating Factors:
Somatic Sensitization
Illness Distress:
Health Related Qualify of Life

Perpetuating Factors:
Cognitive and Emotional Representations of Illness

Figure 2. Application of the cognitive behavioral model of medically unexplained
symptoms. Adapted from “The cognitive behavioural model of medically unexplained
symptoms: a theoretical and empirical review,” by Deary, V., Chalder, T., & Sharpe, M.
(2007). Clinical Psychology Review, 27, p. 9. Copyright 2007 by Elsevier Ltd.
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Although research has supported many individual components of the cognitive
model of MUS including the impact of personality (De Gucht, Fontaine, & Fischler,
2004; Deary, Scott, & Wilson, 1997), gender (Wool & Barsky, 1994), illness perception
(Dorrian et al., 2009) and body vigilance (Keough, Timpano, Zawilinski, & Schmidt,
2011) with the subjective experience of illness, this body of literature is incomplete.
Despite ample theoretical support, the current body of empirical research has failed to
include the critical role of somatic sensitization in the context of other components of the
CBT model of MUS. The purpose of the proposed research is to test the unique role of
body vigilance as a contributor to MUS, as predicted in the CBT model of MUS, and in
the process to create a more complete and accurate test of the model.
Applying the CBT model of MUS presents several practical challenges. By
definition, MUS describes a broad category of conditions, and due to the limited scope of
the present study it is not feasible to include all conditions for which symptom-related
distress exceeds physiological explanation. Further, since the relationship between body
vigilance to well-being has not been examined in the context of MUS, the relative
strength of associations is unknown. Before this relationship can be applied to the
broader class of MUS, it must be demonstrated in a model population of MUS. The
present study uses a single type of illness to demonstrate the impact of body vigilance in
development and maintenance of MUS. In the following section, the rationale used to
select Inflammatory Bowel Disease as a prototypical example of MUS will be discussed.
MUS Case in Point: Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD), including both Crohn’s Disease (CD) and
Ulcerative Colitis (UC) is a chronic, relapsing and remitting, autoimmune disease
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affecting approximately 1.4 million people in the United States (Kiebles, Doerfler, &
Keefer, 2010). Both Crohn’s disease and ulcerative colitis are organic, physiologically
based diseases characterized by intermittent “flares” of the immune system, in which an
excessive immune response to intestinal conditions results in inflammation and ulceration
in the intestinal lining. Common symptoms include pain, nausea, and weight loss, as well
as frequent painful, urgent and sometimes bloody bowel movements (Kalibjian, 2003;
Sklar & Sklar, 2007). There is no consensus in the medical community regarding the
cause of the disease; however it is generally accepted that both genetics and environment
are influential (CCFA, 2009; Sklar & Sklar, 2007).
Like its functional analog, irritable bowel syndrome (IBS), IBD often involves
illness-related distress in the absence of disease activity. Unlike IBS, a diagnosis of
Crohn’s disease and ulcerative colitis requires confirmation of physical pathology and
involves substantial blood tests and imaging including CT scans and MRIs, colonoscopy
and endoscopy with biopsies (Kalibjian, 2003; Sklar & Sklar, 2007) and can therefore be
distinguished from somatization disorder. This distinction is important given the history
in the medical community of dismissing unexplained or under-explained conditions as
psychogenic, or symptoms of conversion disorder or malingering. By using a condition
with a clearly evident physiological component, these labels may be avoided. IBD
represents a particularly good fit for the CBT model of MUS previously discussed in this
chapter. As is the case with other forms of MUS, people with diagnoses of IBD are at
particular risk for psychological distress (Schwarz & Blanchard, 1990; Searle & Bennett,
2001) and have lower average quality of life than healthy peers (Cohen et al., 2003;
Dorrian et al., 2009). Of the variables noted in the CBT model of MUS, people with IBD
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typically score higher on measures of trait neuroticism as well as alexithymia as
compared to controls (Moreno-Jiménez, López Blanco, Rodríguez-Muñoz, & Garrosa
Hernández, 2007), and female gender appears to be associated with greater reported
distress (Casellas et al., 2005; Casellas, Lopez-Vivancos, Casado, & Malagelada, 2002).
IBD patients with clinical depression show elevated disease activity evidenced by
increases in several biomarkers for inflammation (Miller, Rohleder, Stetler, &
Kirschbaum, 2005). Higher levels of anxiety and lower health-related quality of life are
associated with greater medical relapse and increased disease activity (Mittermaier et al.,
2004), indicating a possible autopoietic feedback relationship consistent with the CBT
model of MUS.
The course of the disease is unpredictable, and painful symptoms may appear
with little warning, creating ideal conditions for somatosensory amplification (Barsky &
Wyshak, 1990). Treating co-occurring psychological disturbances then may help not only
the subjective experience of the patient, but may reduce the severity of the physical
illness.
Given the complex nature of symptom experience, the impact of symptoms on
quality of life, and the risk for somatosensory amplification, IBD presents an ideal
opportunity to study the influence of body vigilance in the development and maintenance
of medically unexplained symptoms. The present study addresses this potential feedback
system by testing body vigilance as a predictor of health-related quality of life and thus as
a potential sensitizing and precipitating factor in the CBT Model of MUS.
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Relevance to the Field of Counseling Psychology
The likelihood of psychologists encountering a client with a medically
unexplained symptom is high, particularly for those working in primary care settings or
in collaboration with medical doctors in behavioral health and preventive medicine
settings. As the instance rate of chronic conditions increases and the number of patients
whose distress exceeds medical explanation continues to grow, the importance of
psychologists in treatment will likewise increase.
Further, pressure by managed care organizations to employ empirically supported
treatments, and psychologists’ ethical duty to provide the best possible care makes
evident the need for research in this area. Cognitive behavioral therapy has produced the
most empirically validated treatments for the population with MUS, and the CBT model
of MUS is the predominant guiding theory for treatment. Evidence that increased body
vigilance is associated with greater MUS severity will give valuable insight to
psychological interventions that could reduce subjective distress.
Research Hypothesis
Although there is support for several individual components of the CBT model of
MUS including predisposing and perpetuating factors, less is known about what
precipitates the experience of medically unexplained and under-explained symptoms.
Research has shown that stable personality traits, such as neuroticism and alexithymia,
contribute to and possibly predispose a person to heightened illness-related distress in
patients with IBD. Additionally, it has been demonstrated that illness perceptions predict
distress and health related quality of life. Although the CBT model of MUS predicts the
role of feedback, support for the role of body vigilance in illness-related distress is
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limited and has not been investigated in the context of MUS. The purpose of this study is
to include body vigilance in the cognitive behavioral model to determine if body
vigilance predicts unique variance in illness-related distress in IBD, over the variance
accounted for by known predictors of illness-related distress. Specifically, the hypothesis
in the proposed study is that, after controlling for the variance in health-related quality of
life explained by predisposing factors (gender, neuroticism and alexithymia,) and
perpetuating factors (chronicity, cyclical timeline, consequences, personal control,
treatment control, illness coherence and emotional representation), the precipitating
factor body vigilance will account for significant additional variance in health-related
quality of life.
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Chapter 2
Literature Review
Introduction
Improvements in biomedical knowledge and the efficacy of treatment in many
common illnesses have changed the landscape of medical illness. While Western
medicine has traditionally conceptualized illness as primarily acute conditions having
discrete causes, predictable courses, and common symptoms and treatments, medical
illness is increasingly becoming conceptualized as a chronic state (Fennell, 2003). Due
in part to improvement in diagnosis and treatment of medical conditions, enough patients
are now living long enough with illness to make chronic conditions a common
occurrence (Fennell, 2003; Nettleton et al., 2005). Chronic illnesses are often difficult to
treat and do not have single causes or predictable courses (Fennell, 2003). Despite
advances, a significant amount of illness, pain and discomfort remains medically
unexplained and poorly understood (Nettleton et al., 2005).
Defining Medically Unexplained Symptoms
Medically unexplained symptoms (MUS) have been defined in a variety of ways,
and a single useful definition has been elusive (Deary et al., 2007). Alternatively labeled
medically unexplained physical symptoms (Kleinstäuber, Witthöft, & Hiller, 2010) or
unexplained complaints (Koch et al., 2007), definitions most often fall into three groups
(Deary et al., 2007). The broadest definitions refer to MUS as the occurrence of
symptoms in the absence of obvious pathology (Fink, Sorensen, Engberg, Holm, &
Munk-Jorgensen, 1999). A more specific definition identifies MUS as specific individual
clinical syndromes including chronic fatigue syndrome (CFS), fibromyalgia (FM), and
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irritable bowel syndrome (IBS) amongst others. A third category of definition uses MUS
euphemistically to refer to a subset of DSM-IV somatoform disorders (De Waal, Arnold,
Eekhof, & Van Hemert, 2004). This type of definition is the least helpful since even
when physicians in primary care believe that patients meet criteria for somatoform
disorders, they are reluctant to attach such labels to patients, leading to a gross
underestimate of patients with MUS (Swanson et al., 2010). The prevalence rate of MUS
varies according to the stringency of the definition, from over 60% of primary care
consultations using the broadest definition (Fink et al., 1999) to 11% using the most
restrictive definition (Ring, Dowrick, Humphris, & Salmon, 2004). Kirmayer et al.
described MUS as a predicament, not a specific disorder (Kirmayer, Groleau, Looper, &
Dominicé, 2004), and most theory-driven research on MUS has favored a simpler and
less restrictive definition (Aiarzaguena et al., 2008; Deary et al., 2007; Escobar et al.,
2010; Kroenke, 2000; Nettleton et al., 2005; Swanson et al., 2010). For the purposes of
the proposed study, MUS will be defined as patient-reported physical symptoms that are
not adequately explained by underlying physical pathology.
Implications of medically unexplained symptoms. Medically unexplained
symptoms (MUS) are both commonplace and problematic to health care providers,
making up nearly half of all consultations in primary care and hospital outpatient clinics
(Price, 2008). General practitioners often feel frustration in balancing diagnostic
skepticism with their duty to diagnose and relieve patients’ suffering (Aiarzaguena et al.,
2008) and sometimes feel pressure directly from the patient for aggressive treatment
(Ring et al., 2004). As a result, patients with MUS typically use health care services at
high rates and receive expensive and sometimes unnecessary tests and treatments
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(Aiarzaguena et al., 2008; Ring et al., 2004). Patients may fall into a “chronic treatment
trap” described by Peck and Love (1986) in which failed treatment frustrates medical
providers, who label the unexplained distress as psychogenic in nature and refer to mental
health providers for assistance. Patients then try to prove that distress is “real” and may
become resistant or begin treatment-shopping for other providers whom they believe may
be able to help them. As both patient and provider become frustrated, positive treatment
outcomes become less likely. Patients with medically unexplained symptoms have
approximately twice the outpatient and inpatient medical care utilization and twice the
annual medical care costs of non-somatizing patients (Barsky, Orav, & Bates, 2005).
A particular challenge in treating patients MUS is “somatically focused” health
beliefs that lead to an exaggerated perception of the importance of “true diagnoses” and
“correct medical treatment,” which in turn fuels dependence and overutilization of
medical services (Kleinstäuber et al., 2010). In light of this overemphasis, psychosocial
factors may initially be neglected and only addressed when first attempts have failed
(Van Eijk et al., 1983). The shift in focus is often associated with a deterioration of the
physician-patient relationship, as patients think that the physician has lost interest in them
or views them as annoying (Kirmayer, 1994). Effective treatment of MUS involves
collaboration between patient and health care provider in determining treatment goals
including behavior modification, physical activity and increasing active coping
(Kleinstäuber et al., 2010; Richardson & Engel, Jr., 2004) .
The chronic nature of MUS leads to decreases in activity levels, working capacity and
role functioning (De Waal et al., 2004). Patients with chronic somatic symptoms
experience psychological distress at higher rates than their healthy peers (Bohlmeijer et

18

al., 2010) including a rate of depression approximately 50% higher than peers without
medical illness (Patten, 2001). This is true regardless of medical explanation of one’s
condition (Escobar et al., 2010). In a study by Barsky et al. (Barsky et al., 2005) 31% of
the participants with somatic symptoms fulfilled criteria of a major depressive disorder
and 19% had a panic disorder. Likewise, patients with MUS experience significant
psychological distress, high levels of medication use (Katon, 2003) and lower overall
quality of life (Aiarzaguena et al., 2008; Feder et al., 2001; Kleinstäuber et al., 2010).
Medically unexplained symptoms are associated with distress and disability that is at
least as severe as medically explained symptoms (Price, 2008). In fact, medical
explanation is less important in predicting mood disorders such as depression and anxiety
than the number of somatic complaints endorsed (Escobar et al., 2010). Regardless of
full and accurate medical explanation of one’s illness, somatic experiences appear to be a
driving force in illness-related distress. Consequently, measures of health-related quality
of life (HRQOL) that describe patients’ subjective experience are appropriate and useful
in treating chronic disease (Fitzpatrick, Davey, Buxton, & Jones, 1998) since they
provide a more accurate representation of the experience of illness than specific clinical
indicators (Han et al., 2005).
Although data pertaining to a patient’s physiological state may be useful to a
healthcare provider, it does not necessarily translate to functional capacity or well-being
of the patient. Patients with similar clinical data may have vastly different levels of
functional impairment or psychological distress (Guyatt, Feeny, & Patrick, 1993).
Common measures of disease-specific health related quality of life typically include
dimensions capturing specific and systemic symptoms, and social and emotional
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functioning (Cohen, 2002). Health-related quality of life is a composite measure that is
commonly used to assess the multidimensional impact of chronic disease (Guyatt et al.,
1993).
Psychological conceptualization of medically unexplained symptoms. There is
considerable support for cognitive behavioral therapy (CBT) both as a model for (Deary
et al., 2007; Mai, 2004; Neimark et al., 2005), and as an effective treatment of MUS. The
cognitive behavioral model of medically unexplained symptoms (CBT Model of MUS)
(Deary et al., 2007) helps explain the dynamic relationship between correlates of illnessrelated distress that both prime and perpetuate the experience of aversive symptoms even
in the absence of direct physiological causes. Based on Beck’s cognitive theory, the
cognitive behavioral model of MUS separates correlates of MUS into predisposing,
precipitating, and perpetuating factors in the development and maintenance of emotional
distress. People experiencing MUS are believed to have certain vulnerabilities and
characteristics, for example, genetics and personality traits that increase both the instance
rate and the severity of unexplained distress. Perpetuating factors are those elements that
serve to maintain the symptoms such as cognitive processes, physiological arousal,
behaviors and social factors. Precipitating factors are those which influence or trigger
distress such as one’s distress tolerance (Deary et al., 2007). The CBT model of MUS
model differs from traditional bio-psycho-social conceptualizations in the inclusion of
mutual and reciprocal feedback which self-maintains in the absence of physical
pathology, a process Deary et al. describe as “autopoietic” (Deary et al., 2007). A
description of the general model CBT Model of MUS can be found in chapter 1.
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Applying the CBT model of MUS presents several practical challenges. MUS is
by definition a broad category of conditions, and due to the limited scope of this study it
is not feasible to include all conditions for which symptom-related distress exceeds
physiological explanation. Before this relationship can be applied to the broader class of
MUS, it must be demonstrated in a model population of MUS. This study uses a single
type of illness to test whether body vigilance predicts unique variance in health-related
quality of life and thereby shed light on the potential impact of body vigilance in
development and maintenance of MUS. The following section will explain the rationale
used to select Inflammatory Bowel Disease as a prototypical example of MUS.
MUS Case in Point: Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD), including both Crohn’s disease and
ulcerative colitis, is a chronic, relapsing and remitting, autoimmune disease affecting
approximately 1.4 million people in the United States (Kiebles et al., 2010). Both
Crohn’s disease and ulcerative colitis are organic, physiologically-based diseases
characterized by intermittent “flares” of the immune system, in which an excessive
response to normal intestinal bacteria results in inflammation and ulceration in the
intestinal lining. Common symptoms include pain, nausea, weight loss, frequent, painful,
urgent and sometimes bloody bowel movements (Kalibjian, 2003; Sklar & Sklar, 2007).
If untreated, flares cause ulcerations accompanied by pain, obstructions and the danger of
perforation which may be fatal (Kalibjian, 2003; Sklar & Sklar, 2007). While Crohn’s
disease can occur at any point in the gastrointestinal tract, ulcerative colitis is by
definition limited to the colon. There is no consensus in the medical community
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regarding the cause of the disease; however it is generally accepted that genetics and
environment are influential (CCFA, 2009).
Like its functional analog, irritable bowel syndrome (IBS), IBD can be considered
a medically underexplained condition since illness-related distress may occur in the
absence of disease activity. Unlike IBS, a diagnosis of IBD requires confirmation of
physical pathology and involves substantial blood tests, imaging including CT scans and
MRIs, colonoscopy and endoscopy with biopsies (Kalibjian, 2003; Sklar & Sklar, 2007)
and can therefore be distinguished from somatization disorder.
Patients with IBD are at particular risk for psychological distress (Schwarz &
Blanchard, 1991; Searle & Bennett, 2001), score higher on measures of alexithymia
(Moreno-Jiménez et al., 2007) and have lower average quality of life than healthy peers
(Cohen, 2002; Dorrian et al., 2009). IBD patients with clinical depression show elevated
disease activity evidenced by increases in several biomarkers for inflammation (Miller et
al., 2005), highlighting the dynamic and recursive nature of psychological and physical
symptoms. Higher levels of anxiety and lower health-related quality of life are associated
with greater medical relapse and increased disease activity (Mittermaier et al., 2004),
indicating a possible autopoietic feedback relationship consistent with the CBT model of
MUS. The course of the disease in unpredictable, and painful symptoms may appear
with little warning, creating ideal conditions for somatosensory amplification (Barsky &
Wyshak, 1990). Treating co-occuring psychological disturbances then may help not only
the subjective experience of the patient, but may reduce the severity of the physical
illness.
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Because there are currently no prospects for a cure in patients with IBD, treatment
focuses on prevention of complications, induction and maintenance of remission, and
improvement and preservation of quality of life. The onset of IBD occurs most
frequently in young adulthood, with a modal age in the early 20s, and results in no
change to average lifespan (Kalibjian, 2003; Sklar & Sklar, 2007). No two cases of IBD
are alike (Sklar & Sklar, 2007) and, adding to the complexity, subjective distress does not
always correlate to disease activity, even in cases of medical urgency (Dorrian et al.,
2009; Han et al., 2005; Kim et al., 1999). Patients with IBD will likely live with the
condition for many years, adding to the potential impact of improving subjective wellbeing.
Measures of health-related quality of life are accepted as appropriate outcome
indicators in chronic disease (Fitzpatrick et al., 1998) because they may represent more
accurately the complete experience of the individual than do indices based solely on
clinical measures. In the specific case of evaluating outcomes for patients with IBD,
HRQOL has been indicated as an appropriate outcome measure for treatment (Cohen,
2002) since health status cannot be explained adequately by symptom and disease-related
measures. Psychosocial factors such as illness worry and daily functioning impairment
would otherwise be missed using only medical benchmarks for disease activity
(Drossman et al., 1999). Identifying the factors associated with poor quality of life can
aid clinicians in anticipating problems that patients may have and in targeting therapeutic
interventions more appropriately (Han et al., 2005).
Measures of HRQOL among patients with IBD, even those with minimal symptoms,
show markers of distress not only due to systemic and bowel symptoms, but functional

23

impairment, social impairment and emotional functioning compared to age and sex
matched controls (Love, Irvine, & Fedorak, 1992). This indicates a broad-reaching
negative impact on quality of life.
In an apparent contradiction to these results, one study found that, among patients
admitted to a hospital, those with Crohn’s Disease, a specific form of IBD, had higher
socioeconomic level, lower unemployment, greater job stability and fewer absences due
to sick leave than age and sex matched controls (Sørensen, Olsen, & Binder, 1987). This
finding seems contrary to the previously discussed impairments associated with IBD.
Although research has suggested a relationship between IBD and various forms of
impairment, it seems logical that the looming, unpredictable threat of hospitalization
could cause patients with IBD to use sick days judiciously, whereas non-ill patients feel
more comfortable with less of a buffer. Similarly, patients with IBD may be less likely to
leave the security of jobs that offer health insurance, paid time off for medical leave,
disability insurance, retirement plans and other such benefits. Job stability in this context
could be viewed as an indicator of fear of job loss rather than high performance or job
satisfaction. In line with this interpretation of absences, unemployment and
socioeconomic status, 54% felt that their disease strained their professional and personal
life, 23% reported decreased working capacity, and 21% reported decreased leisure
activities (Sørensen et al., 1987). It is plausible, then, that just as physiological markers
sometimes fail to capture the subjective impact of chronic illness-related distress, some
common markers used in work-related studies (e.g., socio-economic status,
unemployment, and number of medical leave days used) may miss the nuances of workrelated impairment due to MUS.
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Given the complex nature of symptom experience, the impact of symptoms on
quality of life, and the risk for somatosensory amplification, IBD presents an ideal
opportunity to study the relationship of body vigilance in the development and
maintenance of medically unexplained symptoms.

The following sections will elaborate

on the CBT Model of MUS, and provide an in-depth discussion of the component factors
and their relationship with HRQOL.
Predisposing factors. Among the factors believed to predispose one to medically
unexplained illness are genetics, personality types and early experiences. Deary et al.,
describe genetics as one of the less understood links to MUS (Deary et al., 2007). This is
understandable given the broad spectrum of conditions that are included under the
umbrella of MUS. There is support, however, for individual medically unexplained and
under-explained conditions, including: chronic fatigue (Afari & Buchwald, 2003),
fibromyalgia (Buskila & Sarzi-Puttini, 2006), irritable bowel syndrome (Gonsalkorale,
Perrey, Pravica, Whorwell, & Hutchinson, 2003; Levy et al., 2001) and inflammatory
bowel disease (Bonen & Cho, 2003; Bouma & Strober, 2003; Yang & Rotter, 2005).
Genetics are widely believed to contribute to IBD (Kalibjian, 2003; Sklar & Sklar,
2007). A study investigating the genetic influence of IBD found that monozygotic twins
with Crohn’s disease have a concordance rate of 58%, while dizygotic twins exhibited a
rate of is only 3.9%. A similar pattern was observed in ulcerative colitis in which a 50%
concordance rate in monozygotic and none of the dizygotic participants had twins with
UC (Tysk, Lindberg, Järnerot, & Floderus-Myrhed, 1988). This evidence strongly
supports a genetic component to the development of IBD, though it is likely that the
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interaction is complex and involves interaction with both environmental and dispositional
factors (Bouma & Strober, 2003).
Gender. Though a specific genetic marker for IBD is elusive, gender, which reliably
coincides with chromosomal sex, is a risk factor for MUS in general (Nimnuan, Hotopf,
& Wessely, 2001; Wool & Barsky, 1994). Social factors may explain some of this effect,
including lower barriers to admitting discomfort, greater willingness to seek medical
attention and differences in prevalence of psychiatric conditions with somatic features,
and increased risk of childhood physical or sexual trauma and resulting differences in
bodily perception (Nimnuan et al., 2001; Wool & Barsky, 1994).
A study of medically unexplained symptoms of pain in women undergoing
laparoscopic surgery showed that a history of severe sexual abuse was positively
associated with psychiatric disorders and unexplained chronic pelvic pain (Walker,
Katon, Roy-Byrne, Jemelka, & Russo, 1993). Walker followed this study with an
investigation of the influence of childhood sexual abuse on irritable bowel syndrome and
inflammatory bowel disease and found significant differences between the conditions on
rates of victimization and subsequent mental health issues including depression, panic
and generalized anxiety disorders (Walker, Gelfand, Gelfand, & Katon, 1995). Fifty-four
percent of women with IBS reported histories of sexual assault, 76% depression, 41%
panic disorder and 58% generalized anxiety. In contrast, 42% of the women with IBD
reported sexual abuse, 45% reported histories of depression, 25% panic disorder, and
35% generalized anxiety disorder (Walker et al., 1995). Of note in this study, patients
without pathological inflammation of the gastrointestinal tract, that is, those with IBS,
showed a level of functional disability equal to or greater than patients with severe
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organic symptoms of IBD. Female gender is also associated with increased symptom
severity and lower HRQOL in IBD (Casellas et al., 2002), although the relationship is
diminished controlling for perceived symptom severity (Han et al., 2005).
Personality factors. Personality factors are known to influence medical patients’
reports of symptoms and health (Costa, 1987; Larsson, Lööf, Rönnblom, & Nordin, 2008;
Lawson, Bundy, Belcher, & Harvey, 2010). Most of the literature on personality and
MUS has focused on negative affectivity or neuroticism, two similar constructs, to
describe a general disposition to experience subjective distress, including aversive mood
states such as anger, disgust, scorn, guilt, fearfulness and depression (Moreno-Jiménez et
al., 2007; Watson & Clark, 1984; Watson & Pennebaker, 1989). With a heritability of
approximately 50% (Matthews, Deary, & Whiteman, 2003), neuroticism could help
explain part of the genetic link of IBD.
Neuroticism is associated with several mechanisms of the cognitive model including
harm avoidance (Cloninger, 1987), increased generalization of conditioned response
(Bergh, Winters, Devriese, & Diest, 2002), increased experience of physical symptoms
after an aversive stimulus (Petrie, Moss-Morris, Grey, & Shaw, 2004), disproportionate
attention to pain or fear (Matthews et al., 2003), compromised immune activity
(Marsland, Cohen, Rabin, & Manuck, 2001), increased instances of negative life events
(Kendler et al., 2003; Magnus, Diener, Fujita, & Payot, 1993), and greater reactivity to
negative life events (Bolger & Schilling, 1991).
Neuroticism is related to poorer HRQOL in general populations (Kressin, Spiro III, &
Skinner, 2000) and in patients with chronic health conditions (Patten, 2001). Negative
affect is an important determinant for the development and maintenance of MUS (De
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Gucht et al., 2004). Among patients with IBD, Neuroticism is correlated with selfesteem (r = -.50; p < .001), the predisposing factor alexithymia (r = -.48; p < .001), and
all four domains of HRQOL including bowel symptoms (r = -.45; p < .001), systemic
symptoms (r = -.52; p < .001), emotional functioning (r = -.62; p < .001) and social
functioning (r = -.41; p < .001) (Moreno-Jiménez et al., 2007).
Alexithymia is a second dimension of personality that relates to one’s ability to
recognize and regulate emotional distress. Literally meaning “no words for feelings,”
alexithymia has three facets, difficulty identifying and describing feelings (DIF),
difficulty in distinguishing between feelings and bodily sensations of emotional arousal
(DDF), and the tendency to focus on the concrete details of external events (EOT)
(Lesser, 1981; Nemia et al., 1976; Taylor 1984). Higher levels of alexithymia are
associated with greater somatic distress, both among patients receiving medical care and
in nonclinical populations (Bailey & Henry, 2007; Deary et al.,1997).
Alexithymia and emotional control are negatively related constructs that address
one’s ability to access, recognize and express one’s emotional state. In a study
investigating the influence of both variables on HRQOL on patients with IBD, Verissimo,
Mota-Cardoso, and Taylor (1998) found that, although they did not predict duration of
illness and level of disease activity, emotional control and alexithymia independently
predicted HRQOL. Emotional control was related to a composite score of HRQOL (r =
.37; p < .01) as well as each of its component domains: bowel symptoms (r = .26; p <
.01), systemic symptoms (r = .42; p < .01) and emotional symptoms (r = .43; p < .01).
This shows that greater emotional control is associated with improvement in symptoms,
functioning and well-being. Not surprisingly, alexithymia, measured by the Toronto
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Alexithymia Scale (TAS-20) showed an inverse correlation with total HRQOL (r = -.34;
p < .01) as well as each of its component domains: bowel symptoms (r = -.28; p < .01),
systemic symptoms (r = -.37; p < .01) and emotional symptoms (r = -.38; p < .01),
indicating that as difficulty identifying and describing feelings, and externally oriented
thinking increase, symptoms increase and functioning and well-being decrease.
Predisposing factors gender, neuroticism and alexithymia are all predictive of greater
illness-related distress evidenced by lower scores on HRQOL among people diagnosed
with IBD. The CBT Model of MUS holds that once the illness-related distress is present,
perpetuating factors maintain and even amplify this distress. The following section will
address perpetuating factors in the case example of people with IBD.
Perpetuating factors. The CBT model of MUS holds that cognitive and
behavioral factors predict both the development and maintenance of medically
unexplained symptoms in a self-reinforcing autopoietic system. These perpetuating
factors include the development of illness-related cognitions, coping strategies to reduce
the effects of distressing symptoms and the process of sensitization to aversive stimuli
and precipitants to distress (Deary et al., 2007).
Cognitive representation of illness. Illness representation is a concept that
describes an individual’s cognitive and emotional representations used to make sense of
one’s illness. The interpretation of this information is instrumental in shaping the way a
person affected by illness adapts to and engages with his or her condition (Hagger &
Orbell, 2003). The “common sense model” (CSM), originally proposed by Leventhal,
Meyer, and Nerenz (1980), proposes that individuals construct cognitive representations
of their illness from their cultural knowledge of illness, from persons holding authority,
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and from their own experience with illness, and organize this representation along
dimensions of cause, consequences, identity and timeline (Hagger & Orbell, 2003).
The “cause” dimension represents a person’s beliefs regarding the origin and
etiology of the illness. An example would be the belief that one’s condition is the result
of pathogens, stress, or environmental pollutants. The “consequences” dimension of
illness representation refers to a person’s belief of the impact that illness will have on his
or her functional capacity and quality of life. The belief that illness will prevent a person
from engaging in pleasurable activities or performing activities of daily living would
indicate high consequences. The “identity” dimension refers to the particular label a
person ascribes as the source of illness. A person with cancer who attributes nausea to
chemotherapy would have a markedly different representation from a person whose
nausea is idiopathic and mysterious to him or her. The “timeline” dimension refers to the
belief in the chronicity of the condition, or in other words the likelihood that it will be
resolved or persistent. Recent research has added a fifth dimension assessing the
controllability of an illness (Hagger & Orbell, 2003; Moss-Morris et al., 2002).
The common sense model has been operationalized by the illness perception
questionnaire (IPQ-R; Moss-Morris et al., 2002) with demonstrated use in many
conditions including rheumatoid arthritis, COPD and psoriasis (Scharloo et al., 1998),
asthma (Leventhal et al., 1992), chronic fatigue syndrome (Heijmans & de Ridder, 1998),
irritable bowel syndrome (Rutter & Rutter, 2002), and IBD (Dorrian et al., 2009).
Dorrian and Dempster (2009) investigated whether illness perception predicted
psychological distress, health-related quality of life and functional independence among
patients with IBD. In this study, the IBD-Q, an IBD-specific measure of quality of life,
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was reverse-coded, and positive correlations indicated inverse relationships. The authors
found that scores on the “identity” scale of the IPQ-R, which measures belief in an
attributable cause of symptoms, was related with poorer quality of life (r = .50; p <
.001). Likewise higher scores on the “acute/chronic” scale, indicating belief in a chronic
rather than acute timeframe for illness, were related to poorer quality of life (r = .33; p <
.002). Higher scores on the “cyclical timeline” scale, indicating belief in a variable and
unpredictable course of illness (r = .42; p < .001), and the “consequences” scale,
indicating belief of severe consequences of illness (r =.58; p < .001), were both related to
poorer quality of life. These results support the role of cognitive representations as an
influence in the experience of illness as predicted by the CSM of illness representation
and the CBT model of MUS.
Sensitization. Deary et al. (2007) define sensitization as the tendency for an
individual to have a heightened response to stimuli because of prior experience, most
likely in the presence of painful or stressful stimuli that are both uncontrollable and
unpredictable, (Rygh et al., 2005). The process of sensitization in the context of MUS
was first described by Barsky and Wyshak, in reference to hypochondriasis (Barsky &
Wyshak, 1990). Termed somatosensory amplification, patients with unexplained somatic
symptoms disproportionately attend to benign somatic sensations, misinterpreting them
as serious threats and amplifying both attention and resulting distress. The CBT model of
MUS predicts that a similar process takes place among non-hypochondriac population
with MUS. In the predicted model, greater perception of and attention to distress
mutually and reciprocally influence cognitions, and the result of this feedback loop is a
lowered physiological threshold and greater reactivity to aversive experience (Deary et
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al., 2007). Thus, sensitization is both an effect of, and secondary cause of prolonged
distress. The following section will discuss the role of sensitization in precipitating
distress.
Precipitating factors. The CBT model of MUS, illustrated in chapter 1, page 10,
outlines the relationship between predisposing, precipitating and perpetuating factors in
the development and maintenance of illness-related distress, including a mutual and
reciprocal relationship between perpetuating and precipitating factors. In the proposed
study, sensitization serves this function, as both a result of prolonged distress which
increases the likelihood of future detection of symptoms, resulting in distress.
Overmier and Murison (2005) found support for this feedback cycle in persons
exposed to trauma or chronic stress. Among the effects observed were greater reactivity
in the hypothalamic-pituitary-adrenal axis, and greater gastrointestinal vulnerability to
ulcers, impaired cognition, suppressed emotional expression, and exacerbations in IBD
(Overmier & Murison, 2005). For patients with IBD, whose disease induces
gastrointestinal ulcers, and whose symptoms include frequent unpredictable and
uncontrollable pain, the effect of stress appears remarkably similar to disease activity,
thus providing the ideal conditions for the cycle of somatosensory amplification.
Although no studies to date have addressed somatosensory amplification in IBD,
Keough et al. have studied the process in irritable bowel syndrome (IBS). In IBS, many
of the symptoms are similar, including pain and altered bowel habits; however in IBS, no
underlying physiological pathology is present (North, Hong, & Alpers, 2007).
Psychiatric comorbidity is common in IBS, with between 50 and 90% of affected patients
meeting criteria for a psychiatric disorder (Lydiard, 2001). Individuals with IBS also
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report elevated levels of worry, distress, neuroticism and somatization (Gros, Antony,
McCabe, & Swinson, 2009; Hazlett-Stevens, Craske, Mayer, Chang, & Naliboff, 2003;
Van der Veek, Van Rood, & Masclee, 2008), making this study an appropriate functional
analog to IBD. Keough et al. found significant relationships between IBS and distress
intolerance (r = .12; p < .01), anxiety (r = .12; p < .05), depression (r = .09; p < .05) and
body vigilance (r = .13; p < .01). The elevated vigilance to internal bodily sensations
was not accounted for by symptoms of anxiety or depression, lending support to the
mechanism of somatosensory amplification and the independent role of affect, avoidance
behaviors, and body vigilance (Keough et al., 2011).
Purpose of the Study
Medically unexplained symptoms, particularly those associated with chronic
illness, are common occurrences that cause physical discomfort and frustration to
patients, increase the likelihood of clinically significant psychological distress, and
negatively impact multiple aspects of quality of life. Although literature exists describing
the development and maintenance of MUS, the body of research is currently incomplete,
lacking any published test of sensitization, a key component in the context of the
conceptual model. This study attempts to close this gap in the literature by testing body
vigilance as a marker of sensitization, in line with the CBT model of MUS.
Given demographic and epidemiological trends, the likelihood that psychologists-even those in general practice--will encounter clients with MUS is very high. Further,
pressure by managed care organizations to employ empirically supported treatments, and
psychologists’ ethical duty to provide the best possible care, makes evident the need for
research in this area. Cognitive behavioral therapy has produced the most empirically
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validated treatments for the population with MUS, and the CBT model of MUS is the
predominant guiding theory for treatment. Evidence that increased body vigilance is
associated with greater MUS severity will give valuable insight to psychological
interventions that could reduce subjective distress.
Given the complex nature of symptom experience, the impact of symptoms on
quality of life, and the risk for somatosensory amplification, IBD presents an ideal
opportunity to study the influence of body vigilance in the development and maintenance
of medically unexplained symptoms. By testing this model in a population with IBD, this
study attempts to clarify entry points to behavioral health treatment for people living with
a complex and dynamic illness, and potentially improve patient care and patients’
subjective and physical well-being. In the process, use of this population avoids some of
the pitfalls of previous research by eliminating the possibility of purely psychogenic
distress.
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Chapter 3
Method
The purpose of the study is to test whether body vigilance predicts unique
variance in health-related quality of life, and thereby shed light on whether body
vigilance may serve as a precipitating factor of illness-related distress as suggested by
Deary et al.’s ( 2007) cognitive model of medically unexplained symptoms, using the
case example of inflammatory bowel disease. Prior to data collection, the investigation
was approved by the University’s Institutional Review Board.
Participants
Eligible participants were a non-random sample of adult volunteers who selfidentified as having a diagnosis of inflammatory bowel disease, defined as either Crohn’s
disease or ulcerative colitis (CCFA, 2009). Since diagnosis typically involves a
combination of blood tests, radiological imagery, and colonoscopy or endoscopy with
tissue biopsy, self-report of diagnosis from a gastroenterologist was assumed to be an
accurate indication of disease status. Participants under the age of 18 or over the age of
70 were excluded due to potential age related confounds, in line with similar studies (De
Gucht et al., 2004; Moreno-Jiménez et al., 2007).
Sample Size
Sample size for the regression analysis in the present study was determined
following the recommendations made by Cohen (1998) in the second edition of his book
on power analysis. Cohen’s recommendation makes use of a combination of power
tables with adjustments based on approximate effect size of predictor variables.
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Cohen offers an operational definition for small, medium and large effect sizes
represented by R2s of .02, .13, and .26 respectively. By this definition, previous research
has shown, moderate effect sizes connecting neuroticism to MUS (De Gucht et al., 2004)
and health-related quality of life (Moreno-Jiménez et al., 2007), alexithymia to MUS (De
Gucht et al., 2004) illness perception to health-related quality of life (Kiebles et al., 2010)
and body vigilance to severity of MUS (Keough et al., 2011).
Using his base recommendation of 139, adjusted by (m-1) where m equals the
number of predictor variables, with a power of .80 and alpha of .05, a sample size of
approximately 153 participants is indicated. An alternative rule of thumb was proposed
by Harris (1975) suggests a sample size of 50 + 8m, where m equals the number of
predictor variables. This rule of thumb for the present study would indicate a sample
size of 170. Given the tendency of Harris’s rule to overestimate sample size when m > 6
(Green, 1991), the lower of the two recommendations was used and a goal of 153
participants was set. The anticipated sample of 153 exceeded the size of previous
published regression analyses investigating similar constructs (Dorrian et al., 2009;
Kiebles et al., 2010; Moreno-Jiménez et al., 2007).
An a priori power analysis was performed using G*Power software (Franz, 2012)
for an additional estimate of sample size. Prior to this study, there was no basis for
estimating the increase in variance explained by the addition of body vigilance to the
other variables being tested. With a conservative estimated effect size of .05 additional
variance explained by the addition of body vigilance, a power of .80 and alpha of .05, the
G*Power software indicated a sample size of 152 would be required. If the effect size is
changed to include a .10 increase in variance explained, the indicated sample size drops
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to 74. Therefore, a sample size of 154 was assumed to be sufficient to show statistical
significance. The present study included 199 participants in the final analysis, exceeding
all estimates for minimum sample size. A demographic breakdown can be found in the
following chapter.
Recruitment
Participants were recruited in two ways. First, members of the Crohn’s and
Colitis Foundation of America (CCFA) were invited to participate in a study about
factors contributing to health-related quality of life through a posting in the research
section of the CCFA website (Appendix A). CCFA maintains a listing of active research
studies including clinical medical trials and non-medical outcome research such as the
current study. CCFA requires that all projects have statements of compliance with Health
Insurance Portability and Accountability Act (HIPAA) regulations, and requires informed
consent from participants (CCFA, 2011). Each study included in the CCFA registry has a
unique webpage within the CCFA domain and includes a brief description of the nature
of the study and contact information of the lead investigator, should participants have any
questions. A direct link to the online survey was included and a statement of risks and
benefits was included (Appendix A). Consent was implied by navigating to and
completing the survey.
The second method of recruitment involved posting to online IBD-related interest
and support groups with permission of the appropriate group moderator. Groups were
found on Facebook, Google+ as well as state and local CCFA chapters and affiliated
groups. Once approval was granted, a message inviting members to participate,

37

including a link to the above referenced study specific website contained on the CCFA
research page was posted to the respective group message board.
With both methods of solicitation, the descriptions included a statement of
incentives which gave participants the option of a small ($3.00) credit to Amazon.com, or
the addition of the same amount to a group donation made by the investigator to the
CCFA at the conclusion of the study.
Measures
Participants were asked to complete the following measures: a demographics
questionnaire, the 12-item Neuroticism subscale of the NEO Five Factor Inventory (NEO
FFI), the Toronto Alexithymia Scale (TAL-20), the Illness Perception Questionnaire
(IPQ-R), the Body Vigilance Scale (BVS) and the IBD specific measure of health related
quality of life (IBDQ). Time to complete all of the instruments is approximately 45
minutes. Previous research in condition-specific measures of quality of life have not
indicated any effect of instrument order on response outcomes, therefore the likelihood of
order effects in the proposed study is assumed to be low (Mccoll et al., 2003).
Demographic variables. Demographic information (Appendix B) collected for
each participant included background information: age, race, gender, education level; and
disease-specific information including: particular diagnosis, length of time the participant
has lived with the diagnosis, self-report of number of flares in the previous 12 and 24
months. Finally the demographics questionnaire incorporated information relevant to
treatment including surgical and medical interventions.
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Personality variables. Neuroticism and Alexithymia were operationalized by the
Neuroticism subscale of the NEO Five Factor Inventory (Costa & McCrae, 1992) and the
Toronto Alexithymia Scale (Appendix C), respectively.
Neuroticism. Neuroticism, defined as the stable tendency toward negative affect
and cognition, is one of five dimensions of personality proposed by Costa and McCrae’s
five factor model (1992). The NEO Five Factor Inventory (NEO –FFI) is a brief measure
of personality designed to measure the five basic personality factors including
Neuroticism (Costa & McCrae, 1989). The NEO-FFI was derived from the NEO-PI,
taking 12 items per factor from the pool of 180 items on the full NEO Personality
Inventory (NEO-PI) (McCrae & Costa, 1989). The instrument uses a 5-point Likert scale
format with scores ranging from 1 (not very true of me) to 5 (very true of me) for
statements that indicate Neuroticism (e.g., “I often feel tense and jittery.”) In the present
study, only the Neuroticism scale was used.
The NEO-FFI has demonstrated acceptable internal consistency and reliability.
Among adults exhibiting MUS, internal consistency for the Neuroticism scale of the
NEO-FFI is .83 (De Gucht et al., 2004a), similar to young adults in general (Robins,
Fraley, Roberts, & Trzesniewski, 2001). Test-retest reliability was .89 over a span of two
weeks (Robins et al., 2001).
Among the general population, the Neuroticism scale of the NEO-FFI has been
shown to correlate negatively with measures of subjective well-being including the
Oxford Happiness Inventory (r = -.72 ; p < .001 ), the Depression-Happiness Scale (r = .61 ; p < .001 ) and the Satisfaction with Life Scale (r = -.54 ; p < .001) (Hayes &
Joseph, 2003). Neuroticism is also linked with symptom severity in populations with
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MUS (Costa, 1987; Vassend, 1994). In the current study, the Cronbach’s alpha for the
Neuroticism scale of the NEO-FFI in an adult population with IBD was .860.
Alexithymia. Alexithymia is a construct characterized by difficulty identifying
and articulating emotions and distinguishing them from bodily sensations (Nemiah et al.,
1976). The Toronto Alexithymia Scale, TAS-20 (Bagby, Parker, & Taylor, 1994), is a
20-item measure of alexithymia, This well-established personality construct is believed to
inhibit affect regulation (Taylor, Bagby, & Parker, 1999). The TAS-20 has a three-factor
structure comprising the core dimensions of the alexithymia construct including difficulty
identifying feelings (DIF) measured by seven items (e.g., “I am often confused about
what emotion I am feeling”), difficulty describing feelings (DDF) assessed with 5 items
(e.g., “It is difficult for me to find the right words for my feelings”), and externally
oriented thinking (EOT) assessed with 8 items (e.g., “I prefer talking to people about
their daily activities rather than their feelings”) (Bagby et al., 1994). The TAL-20 has
been used in research studies examining influences of MUS in general (Bailey & Henry,
2007; De Gucht et al., 2004a; De Gucht, et al., 2004b; Deary et al., 1997; Jones,
Wessinger, & Crowell, 2006) and with IBD specifically (Moreno-Jiménez, et al., 2007;
Porcelli, Zaka, Centoze, & Taylor, 1981; Verissimo et al., 2000).
Prior to the current study, internal consistency and reliability data were not
presented in published studies in patients with IBD; however, among patients with MUS,
internal consistency was similar to internal consistency among non-ill peers (De Gucht et
al., 2004; Parker et al., 2010). Among patients with MUS, internal consistency was
represented by Cronbach’s alphas of .83 (DIF), .73 (DDF), .and 61 (EOT) (De Gucht,et
al., 2004), estimates that are similar to estimates in other studies of alexithymia in young
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adult populations (Parker et al., 2010). Test-rest reliability is shown by correlations with a
second measure of Alexithymia taken six months later. Correlation coefficients at 6
months for DIF, DDF and EOT were .61, .66, and .73 respectively. In the current study,
internal consistency on the three scales of the TAL-20 among adults with IBD are
represented by Cronbach’s alphas of .843 (DIF), .792 (DDF), and .571 (EOT).
Illness Cognitions. Illness cognitions are the cognitive and emotional
representations that a person forms in response to his or her state of health. The most
common conception of illness cognition derives from the “common sense model” of
illness representation (Leventhal et al., 1980; Leventhal et al., 1984). The Revised Illness
Perceptions Questionnaire (IPQ-R) (Moss-Morris et al., 2002) was used to assess
participants’ cognitive representations of illness (Appendix D). The IPQ-R, a measure
derived from Leventhal’s “common sense model,” organizes cognitive representation of
illness into seven subscales: timeline acute/chronic, timeline cyclical, consequences,
personal control, treatment control, illness coherence, and emotional representation.
The 6-item “timeline acute/chronic” scale measures one’s belief in the chronicity
of the illness (e.g., “my illness will last for a long time,” and “this illness will pass
quickly,” which are reverse-coded.) The 4-item “timeline cyclical” scale addresses
variability in illness over time; sample items include “my symptoms come and go in
cycles” and “my illness is very unpredictable.” The 6-item “consequences” scale
measures the perceived severity and includes “my illness is a serious conditions” and
“my illness strongly affects the way others see me.” The 6-item “personal control” scale
assesses belief in one’s ability to influence the course and severity of symptoms, and
includes “what I do can determine whether my illness gets better or worse” and “I have

41

the power to influence my illness.” The 5-item “treatment control” scale measures belief
in the efficacy of current treatment and includes “my treatment will be effective in curing
my illness” and “the negative effects of my illness can be prevented by my treatment.”
The 5-item “illness coherence” scale is a measure of understanding of one’s illness and
includes “my illness is a mystery to me” (reverse coded), and “I have a clear picture or
understanding of my condition.” Finally the 6-item “emotional representations” scale
asks for specific emotional reactions such as “I get depressed when I think about my
illness” and “my illness makes me feel afraid.”
Since its initial publication, the IPQ and subsequent revision have been validated
and used with numerous illness populations (Moss-Morris et al., 2002) including chronic
fatigue and rheumatoid arthritis (Moss-Morris & Chalder, 2003), multiple sclerosis
(Jopson & Moss-Morris, 2003) chronic obstructive pulmonary disease and psoriasis
(Scharloo et al., 2007, 1998) and recently IBD (Dorrian et al., 2009; Kiebles et al., 2010)
The IPQ-R, when used with individuals with IBD, has generally similar internal
reliability (Cronbach’s alphas ranging from .70 to .83) except for the “treatment control”
scale which, contrary to previous research, showed low internal consistency (α = 20)
(Dorrian et al., 2009). The authors noted that their sample differed from previous
research both in the low internal consistency and in the lack of a relationship between the
“treatment control” scale and their outcome measure of adjustment. They proposed two
possible explanations for the unacceptably low reliability: First, that no validation study
had been conducted with the IBD population, and it is possible that the scale may not fit
this population, particularly given “the incongruence between controllability and
curability” (Dorrian et al., 2009, p. 53). Although it is possible to control symptoms for
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periods of time, IBD is notoriously unpredictable, and there is currently no cure. The
authors noted that other factors including frequency of relapse and hospitalizations were
not assessed in that study, which may influence perception of treatment control. Testretest reliability was not reported and is a possible limitation of using this instrument. In
the current study, the Cronbach’s alpha for the seven subscales of the IPQ-R in an adult
population with IBD were .817 (Timeline: Acute/Chronic), .767 (Consequences), .853
(Personal Control), .704 (Treatment Control), .897 (Illness Coherence), .742 (Timeline:
Cyclical), .894 (Emotional).
Body vigilance. Body vigilance refers to the focusing of conscious attention to
internal somatic sensations including monitoring for disturbance. Schmidt, Lerew, and
Trakowski (1997) conceptualized body vigilance as the learning that takes place, a
“natural consequence” of chronic exposure to aversive stimuli. Body vigilance was
operationalized by the 4-item Body Vigilance Scale (BVS) (Schmidt et al., 1997),
(Appendix E). The first three items assess on a 10-point Likert scale the degree of
attentional focus (e.g., “I am the kind of person who pays close attention to internal
bodily sensations”), perceived sensitivity to changes in bodily sensations (e.g., “I am very
sensitive to changes in my internal bodily sensations”) and the average amount of time
spent attending to bodily sensations (“On average, how much time do you spend each day
‘scanning’ your body for sensations (e.g., sweating, heart palpitations, dizziness)?”). A
fourth item identifies 15 distinct sensations including all of the symptoms of panic attack
as defined by the DSM-IV-TR (American Psychiatric Association, 2000). Participants
are instructed to rate how much they attend to each of these sensations from none (0) to
extreme (10), and an average is computed. The BVS total score is the sum of these four
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items. Principal component analysis of BVS items support a single factor on which all
items load (Schmidt et al., 1997; Vujanovic, Zvolensky, Bernstein, Feldner, & McLeish,
2007). Internal consistency and test-retest reliability are good, with an average
Cronbach’s alpha of .83 in non-clinical samples and a 5 week test-retest coefficient of r
=.68 (Schmidt et al., 1997). No studies to date have validated the BVS for use with IBD
patients; however high internal consistency (Cronbach’s alpha of .95) has been shown in
use with its functional analog, IBS (Keough et al., 2011). The total score (sum of the
four items) will be used for evaluation in this study. In the current study, the Cronbach’s
alpha for the BVS in an adult population with IBD was .771.
Illness distress. Illness distress is a construct encompassing subjective health
status, notably the negative experience of one’s medical condition. In the context of the
CBT model of MUS, illness distress includes the direct discomfort of physical symptoms,
as well as the physical and emotional distress that may be fueled by negative beliefs,
potentially aided by increased detection through higher body vigilance. Whereas
physiological measures often correlate poorly with measures of functional capacity and
well-being, illness distress more accurately captures the total impact of chronic disease
(Guyatt, Mitchel, & Irvine, 1989).
Illness distress in the present study was measured by the 32-item IBD Quality of
Life (IBDQ) scale (Guyatt et al., 1989). Participants were asked to respond to each
question using a 7-point Likert scale ranging from 1 “worst” to 7 “best.” Scores range
from 32 to 224, with higher scores representing better perceived health and functioning.
Developed as an outcome measure for patients with IBD, the IBDQ assesses perceived
functioning and symptom severity across domains including systemic symptoms, bowel
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symptoms, social factors and emotional functioning. The IBDQ is correlated with the
Crohn’s disease activity index (CDAI) (-.50), a common measure of physiological
symptoms, and internal consistency is acceptable for both UC and CD shown by
Cronbach’s alphas of .89 and .85 respectively (Hyphantis et al., 2010). The IBDQ has
greater test-retest reliability at .70 compared to the CDAI’s .66 (Irvine, 1999). Although
comparatively low, the variance in test-retest reliability may indicate that IBD-specific
well-being measured by the IBDQ is a state rather than trait characteristic. This
questionnaire is commonly used in clinical trials as a primary clinical endpoint (Casellas
et al., 2005; Dorrian et al., 2009; Han et al., 2005; Kiebles et al., 2010).
Procedure
Following approval by the University of Memphis Institutional Review Board
(IRB), the study went through an additional review process with the Crohn’s and Colitis
Foundation of America for inclusion on their research study website. Participants were
recruited by the methods described earlier in this chapter and were directed to the study
website with an embedded survey, powered by surveymonkey.com.
Data Analysis
This study used hierarchical multiple regression analysis to determine the relative
contribution of body vigilance as a predictor of health-related quality of life, in line with
the cognitive model of medically unexplained symptoms (Deary et al., 2007).
Hierarchical multiple regression is used to determine the effects of predictors whose
order may be determined a priori by theoretical rationale. The CBT model of MUS
provides such a rationale by organizing factors into temporally distinct categories:
predisposing, precipitating and perpetuating factors. Inherent in this model are
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assumptions of a temporal order. By definition, predisposing factors influence the
likelihood of developing illness and resulting distress that has not yet occurred.
Likewise, precipitants are the proximal triggers to illness distress that may be influenced
by predisposing factors. As a result of the distress, perpetuating factors reinforce the
systemic conditions that created them. Because support exists for all elements of the
CBT Model of MUS except for the influence of sensitization in the form of body
vigilance, in the present study, variables will be entered in the hierarchical regression in
two blocks. The first block included all the variables that current research supports,
including demographic, predisposing and perpetuating variables. Specifically, this
included gender, specific diagnosis, length of time since diagnosis, neuroticism,
alexithymia, as well as all seven dimensions of illness perception illness cognitions. The
second block consisted of the measure of body vigilance. Changes in variance explained
when the second is added can be attributed to body vigilance in the context of all other
elements in the CBT Model of MUS. It is hypothesized that, after controlling for the
variance in health related quality of life explained by predisposing factors (gender,
specific diagnosis, neuroticism, and alexithymia,) and perpetuating factors (chronicity,
cyclical timeline, consequences, personal control, treatment control, illness coherence,
and emotional representation), the precipitating factor (body vigilance) will account for
significant additional variance.
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Chapter 4
Results
This study tested whether body vigilance predicts unique variance in healthrelated quality of life, serving as a precipitating factor of illness-related distress as
suggested by Deary et al.’s (2007) cognitive behavioral model of medically unexplained
symptoms, using the case example of inflammatory bowel disease. This chapter provides
a summary of the statistical analyses used to evaluate the hypothesis established in the
previous chapters, followed by the results of these analyses.
Preliminary Analysis
Hierarchical multiple regression was used to address the research question and
determine whether body vigilance uniquely and significantly explains variance in health
related quality of life. SPSS software v. 21 was used to perform a two-step, hierarchical
multiple regression to determine the influence of body vigilance on health related quality
of life. A three-step regression was then run to determine if non-significant variables,
when entered together in blocks derived from the CBT model of MUS explained
significant variance, supporting the organization of the theoretical model.
After descriptive statistics were reviewed, preliminary analyses were conducted in
order to examine the data for accuracy, missing values, appropriate ranges and
frequencies and normality of distributions. Tests for outliers were conducted to examine
the possibility of potential influential data points.
Prior to analyzing the data, responses were checked for missing, incomplete or
inconsistent data that would warrant exclusion. Of the 300 initial contacts for the survey,
230 participants attempted all survey instruments. Due to incomplete responses or
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missing information, 27 responses were excluded from analysis. Two additional
participants entered responses, which appeared to be typographical errors (entering the
date in which they were diagnosed as a future date). There was no other indication that
these participants were atypical, therefore they were retained in the analysis, and
erroneous scores were replaced with the mean score for length of time since diagnosis.
To assess for curvilinearity and the assumption of homoscedastisity of variance, a
regression was run on the dependent variable (IBDQ). Review of the scatterplot
suggested that curvilinearity was not present in the data and no pattern in the plot
suggested a violation of the assumption of homoscedastisity.
To determine if outliers were influencing the data, a multiple regression was run
and the results were examined to determine if any data points had a Cook’s D value
greater than 1 or a leverage value (n = 203, k = 15) greater than 0.241 (Stevens, 2002).
Regression results indicated that no Cook’s D was greater than .043, and no leverage
value greater than .215. It was determined therefore that there was no significant bias
introduced by outliers. Of the independent variables with significant influence on the
dependent variable, only one scale showed outliers, the consequences scale on the IPR-R
(CONSEQ), which measures the belief of severe consequences because of the
participant’s illness. The distribution of scores on this scale showed a positive skew,
indicating that the majority of participants viewed their disease as having serious
consequences in their lives with four outliers on the low end. Low scores on the
CONSEQ scale suggest that these four participants viewed the consequences of their
disease as notably less serious than the rest of the sample. Each of these participants also
indicated that they were on no maintenance medications, which was atypical for the
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population. Consequently these cases were removed from the final analysis yielding a
sample of 199.
Preliminary analysis indicated there were no multicollinearity problems in the data as
evidenced by variance inflation factors (VIF) of less than 10 (Stevens, 2002), with the
largest VIF being 2.836. Visual review of the scatter plots indicated no curvilinearity in
the data. No pattern suggested a violation of the assumption of homoscedastisity.
Demographic variables including sex (Sex), diagnosis (Dx) and time since
diagnosis (MoSinceDx) were operationalized using demographic information provided
by the participants and are summarized in Table 1. Descriptive statistics for study
variables are presented in Table 2.
Table 1
Demographic Variables
Frequency Percent

Dx

Crohn’s Disease
Ulcerative Colitis

123
76

61.8
38.2

Cumulative
Percent
61.8
100.0

Sex

Female
Male

161
38

80.9
19.1

80.9
100

Race

Caucasian
186
African American
1
Hispanic/Latino
5
Native American/Alaska Native
1
Other
6

93.5
0.5
2.5
0.5
3.0

93.5
94.0
96.5
97
100

Education

High School / No College
Associate’s Degree
Bachelor’s Degree
Master’s Degree
Doctoral/Professional Degree

5.5
24.1
7
37.7
25.6

5.5
29.6
36.7
74.4
100

11
48
14
75
51
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Table 2
Descriptive Statistics
N
Age
199
MoSinceDx
199
N
199
DIF
199
DDF
199
EOT
199
TLAC
199
CONSEQ
199
PRCTRL
199
TXCTRL
199
ILLCOHER
199
TLCYCL
199
EMOT
199
BVSTotal
199

Minimum Maximum
18
66
2
600
14
57
7
35
5
24
8
32
12
30
13
30
6
30
6
24
5
25
4
20
7
30
5.07
40

M
35.08
109.50
35.45
17.31
12.42
17.56
25.75
23.47
21.03
16.42
18.22
14.33
20.19
24.61

SD
12.31
114.48
9.34
6.42
4.62
4.43
3.79
4.17
4.96
3.70
5.24
3.39
5.93
6.94

Sex was given values of 1 (male) and 2 (female). Dx was coded as 1 (Crohn’s
disease) and 2 (ulcerative colitis). For both Sex and Dx, values were chosen arbitrarily.
Time since diagnosis was calculated by subtracting the approximate date of diagnosis
from the date on which the survey was completed.
Participants for the present study were majority female, at 80.9 % (n = 161) as
compared to male at 19.1 % (n = 38), with a diagnosis of Crohn’s disease, 61.8 % (n =
123) as opposed to ulcerative colitis, 38.2 % (n = 76). Self report of race was
predominantly Caucasian at 93.5 % (n = 186), followed in descending order by responses
marked “Other” 3 % (n = 6), “Hispanic/Latino” 2.5 % (n = 5), “African American” and
“Native American/Alaska Native” each with 0.5 % (n = 1). This relative lack of racial
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diversity is a potential limitation in the study and is addressed in the discussion section.
Previous research sampling adults with IBD yielded similar mean age (40) and time since
diagnosis (10.9 years) (Dorrian et al., 2009).
Participants tended to skew disproportionately to higher levels of education with
5.5 % (n = 11) endorsing a highest level of education as “high school with some college,”
24.1 % (n = 48) endorsing “associate’s degree,” 7 % (n = 14) endorsing “bachelor’s
degree,” 37.7 (n = 75) endorsing “master’s degree” and 25.6 % (n = 51) with a “doctoral
or professional degree.”
Internal consistencies for all scales used in the regression analysis were consistent
with those in previous research studies, and are summarized in Table 3. Cronbach’s
alpha of .86 for the Neuroticism scale of the Neo-FFI (N) was similar to the .83 shown in
other MUS populations (DeGucht et al., 2004). Internal consistency for alexithymia
scales of DIF (α = .84), DDF (α = .79) and EOT (α = .57) were likewise similar to
populations with MUS (alphas equal to .83, .73 and .61 respectively) (DeGucht et al.,
2004). Currently the only study to publish internal consistency of IPQ-R scales in IBD
populations, Dorrian et al., (2009) reported alphas ranging from.70 to .83, though did not
specify which alpha applied to particular scales with the exception of treatment control,
for which they found low internal consistency (α = .20). In the present study, all
subscales showed internal consistencies between .70 and .90, including the treatment
control scale. In this way, the current study improves upon existing literature for the use
of the IPQ-R with populations with IBD. Internal consistency for the Body Vigilance
Scale was notably lower with an alpha of .77 as compared to .95 when used in IBS, a
similar but separate medical condition (Keough, et al., 2011). The outcome measure of
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health related quality of life, normed for those with IBD (IBDQ) previously showed
internal consistencies of .89 and .85 for ulcerative colitis and Crohn’s disease
respectively (Hyphantis et al., 2010). Internal consistency for the combined group in the
present study is higher at (α = .94).
Table 3
Reliability Statistics

NEO-FFI: Neuroticism
TAL-20: DIF
TAL-20: DDF
TAL-20: EOT
IPQ-R Timeline Acute/Chronic
IPQ-R Consequences
IPQ-R Personal Control
IPQ-R Treatment Control
IPQ-R Illness Coherence
IPQ-R Timeline: Cyclical
IPQ-R Emotional Reasoning
Body Vigilance Scale (BVS)
Health Related Qualify of Life
(IBDQ)

Cronbach's
Alpha
.86
.84
.79
.57
.82
.77
.85
.70
.90
.74
.89
.77

Number of Items

.94

32

12
7
5
8
6
6
6
5
5
4
6
32

Statistical Analysis
To examine the ability of body vigilance to predict health related quality of life
among the sample population with IBD, study variables were entered into a multiple
regression analysis in two steps, with variables currently supported by research based on
the CBT model of MUS entered in the first step and the study variable, BVS entered in
the second step to determine additional predictive value reflected in change in R squared.
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In the first step, predisposing and perpetuating variables were entered.
Predisposing variables included demographic variables of gender (Sex), specific
diagnosis (Dx), and length of time since diagnosis in months (MoSinceDx), along with
personality variables of neuroticism (N), alexithymia which includes difficulty
identifying feelings (DIF), difficulty describing feelings (DDF) and externally oriented
thinking (EOT). Perpetuating variables included scales of the Illness Perception
Questionnaire Revised (IPQ-R), specifically timeline acute/chronic (TLAC), timeline
cyclical (TLCYCL), consequences (CONSEQ), personal control (PRCTRL), treatment
control (TXCTRL) emotional (EMOT), and illness coherence (ILLCOHER). Body
vigilance (BVS) was entered in the second step as the precipitating factor being tested.
An alpha level of α = .05 was used to assess for statistical significance.
Findings in the current study support previous research that shows correlations
among personality variables, neuroticism and alexithymia. Neuroticism showed
significant correlations with each of the subscales of alexithymia, including DIF (r = .59,
p < .01), DDF (r = .49, p < .01), and EOT (r = .19, p < .01). In this sample, higher
scores on neuroticism were related to increased difficulty identifying and describing
feelings as well as more externally oriented thinking.
Neuroticism also correlated significantly with all scales on the IPQ-R reflecting a
relationship with belief that the illness will be long lasting (r = .15, p < .05), have serious
consequences (r = .38, p < .01). Beliefs that one has personal control (r = -.19, p < .01),
or that treatment will be effective (r = -.22, p < .01), are negatively correlated with
neuroticism. Higher neuroticism was related with a less cohesive understanding of one’s
illness (r = -.26, p < .01), beliefs that symptoms will repeatedly reappear (r = .28, p <
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.01) and greater emotional distress (r = .59, p < .01). Neuroticism also showed a
significant correlation with body vigilance (r = .18, p < .01), and health related quality of
life (r = -43, p < .01). Likewise, alexithymia, a construct that incorporates difficulty
identifying and articulating emotions as well as externally oriented thinking, showed
strong correlations with illness cognitions. Correlations can be seen in Table 4.
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Table 4
Hierarchical Regression Correlations
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

1) IBDQ

--

2) Sex

.02

--

3) Dx

-.06

.04

--

4) MoSinceDx

-.06

-.07

-.18** --

5) N

-.43** .11

-.02

.05

--

6) DIF

-.44** .00

-.09

-.03

.59**

--

7) DDF

-.31** -.11

.01

-.07

.49**

.68**

--

8) EOT

-.12

-.12* -.00

.07

.19**

.29**

.44**

--

9) TLAC

-.13*

.13*

-.17** .10

.15*

.09

.06

.05

--

10) CONSEQ

-.46** -.02

-.07

.04

.38**

.34**

.21**

.03

.31**

11) PRCTRL

.31**

-.13* .07

.01

-.19** -.19**

-.05

-.19** -.33**

-.13*

12) TXCTRL

.31**

.05

.16*

-.18** -.22** -.24**

-.11

-.22** -.41**

-.25** .60**

--

13) ILLCOHER

.28**

.02

.03

.08

-.26** -.41**

-.20** -.26** .00

-.19** .21**

.24**

14) TLCYCL

-.42** .02

-.04

.04

.28**

.42**

.33**

.18**

.04

.24**

-.18** -.15*

15) EMOT

-.52** .11

.00

-.08

.59**

.49**

.32**

.15*

.20**

.53**

-.34** -.30** -.43**

.36**

--

16) BVSTotal

-.25** .04

-.03

-.06

.18**

.23**

.07

-.15*

.07

.14*

.04

.07

.21** --

16

---

.03

--.24**
-.07

--

Note. IBDQ = Health Related Quality of Life in IBD; Sex = reported gender; Dx = diagnosis as either Crohn’s Disease or Ulcerative
Colitis; MoSinceDx = time since diagnosis in months; N = Neuroticism; DIF = difficulty identifying feelings; DDF = difficulty describing
feelings; EOT = externally oriented thinking; TLAC = timeline acute/chronic; CONSEQ = consequences; PRCTRL = personal control;
TXCTRL = treatment control; ILLCOHER = illness coherence; TLCYCL = timeline cyclical; EMOT = emotional consequences;
BVSTotal = composite score of Body Vigilance Scale; *p < .05. **p < .01.

55

Variables entered in step 1 were significant, as shown in Tables 5 and 6, with R2 =
.442, F (14, 184) = 10.426 , p < .01. The addition of body vigilance accounted for an
additional 2.4 % of variance explained, R2 = .466, F(1, 183) = 10.644, p>.01.

Table 5

Model Summary of 2-Step Regression
R

Step 1 .665
Step 2 .683

R2

2

Adjusted R

.442
.466

.400
.422

Std. Error of
the Estimate
26.37718
25.88428

R2 Change

F
Change

df1 df2

Sig. F
Change

.442
.024

10.426
8.074

14 184
1 183

.000
.005

Results of the regression analysis support the hypothesis that body vigilance has a
significant relationship with health related quality of life in addition to what is already
accounted for by variables supported by current IBD research. Effect size for the
additional variance explained is represented by a Cohen’s f2 of .025. In the context of the
full model tested, significant relationships were found between perception of serious
consequences of illness (β = -.234), cyclical timeline (β = -.204), personal control (β =
.168), body vigilance (β = -.165), and specific diagnosis (β = -.123). Personality variables
including neuroticism and all scales of alexithymia, which previously have been
associated with higher distress and lower quality of life among people with MUS, were
not individually significant in this analysis. This appears to contradict previous research
on personality and MUS.

56

Table 6
Summary of Hierarchical Regression Analysis
Unstandardized
Standardized
Coefficients
Coefficients
B
Std. Error
Beta

t

Sig.

Step 1

1. Sex
2. Dx
3. MoSinceDx
4. N
5. DIF
6. DDF
7. EOT
8. TLAC
9. CONSEQ
10. PRCTRL
11. TXCTRL
12. ILLCOHER
13. TLCYCL
14. EMOT

5.017
-8.503
-.022
-.267
-.571
-.382
.629
.544
-1.881
1.045
.709
.187
-1.997
-.924

5.107
4.018
.018
.287
.482
.630
.501
.586
.566
.510
.712
.431
.630
.483

.058
-.122
-.075
-.073
-.108
-.052
.082
.061
-.230
.152
.077
.029
-.199
-.161

.982
-2.116
-1.269
-.930
-1.186
-.606
1.255
.929
-3.324
2.048
.996
.434
-3.168
-1.915

.327
.036
.206
.354
.237
.545
.211
.354
.001
.042
.320
.665
.002
.057

Step 2
1. Sex
2. Dx
3. MoSinceDx
4. N
5. DIF
6. DDF
7. EOT
8. TLAC
9. CONSEQ
10. PRCTRL
11. TXCTRL
12. ILLCOHER
13. TLCYCL
14. EMOT
15. BVSTotal

4.701
-8.613
-.024
-.244
-.299
-.518
.403
.677
-1.911
1.152
.810
.219
-2.045
-.771
-.811

5.013
3.943
.017
.282
.482
.620
.499
.577
.555
.502
.699
.423
.619
.477
.285

.054
-.123
-.082
-.067
-.056
-.070
.052
.075
-.234
.168
.088
.034
-.204
-.134
-.165

.938
-2.184
-1.409
-.863
-.619
-.836
.808
1.174
-3.440
2.295
1.158
.518
-3.304
-1.617
-2.842

.350
.030
.161
.389
.537
.404
.420
.242
.001
.023
.248
.605
.001
.108
.005
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The regression analysis was re-run in three steps (Table 7) corresponding to the
grouping of variables in the CBT Model of MUS with the first step containing only
predisposing variables, the second step adding perpetuating variables and the third step
adding the precipitating variable and completing the model. When run as a three-step
regression, each step showed a significant contribution to variance explained, indicating
that while specific variables which were used as predictors did not explain significant
unique variance in MUS, the conceptual model and theoretically defined grouping of
variables still appears to fit this population.

Table 7

Model Summary of Three-Step Regression
Model
R
R2 Adjusted Std. Error
Change Statistics
2
2
R
of the
R
F
df1 df2
Estimate Change Change
Step 1
.503 .253
.226
29.96
.253
9.257
7 191
Step 2
.665 .442
.400
26.38
.189
8.911
7 184
Step 3
.683 .466
.422
25.88
.024
8.074
1 183
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Sig. F
Change
.000
.000
.005

Chapter 5
Discussion

Medically unexplained symptoms (MUS), defined as sets of symptoms which
physical pathology does not adequately explain (Swanson et al., 2010), are both
commonplace and problematic to health care providers (Kroenke, 2000; Swanson et al.,
2010). In the U.S. between 15% (Aiarzaguena et al., 2008) and 20% (Hartz et al., 2000)
of patients presenting to general practitioners have somatic symptoms with no clear
physiological basis. MUS are particularly challenging to treat for health care providers
(Kroenke, 2000; Raine et al., 2002). Patients with MUS use more health care services
and often receive more tests and treatments at greater cost than may be necessary
(Aiarzaguena et al., 2008). They also experience significant psychological distress and
poorer quality of life (Koch et al., 2007). The impact of MUS extends beyond patient and
provider, as it accounts for a significant proportion of disability in the workforce
(Kroenke et al., 1994; Reid et al., 2001).
The cognitive behavioral model of MUS (Deary et al., 2007) outlines the
relationships between sets of factors believed to be relevant in the development and
maintenance of MUS. These factors are organized into three categories of variables:
predisposing factors which influence likelihood of the symptom first occurring,
precipitating factors which influence the direct triggering of the symptom and
perpetuating factors, those which determine the detection and reactivity to stimuli which
are both effects and secondary causes of the symptom.
While the literature on treating MUS has a solid theoretical grounding in the CBT
Model of MUS, research to date based in this theory has largely neglected precipitating
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factors, a key component in the theoretical framework. Existing studies which show
support for measures of reactivity to MUS in the form of body vigilance (Keough et al.,
2011) have done so without other essential parts of the model, leaving the body of
research incomplete.
This study tested whether body vigilance predicts variance in health-related
quality of life, serving as a precipitating factor of illness-related distress as suggested by
Deary et al.’s (2007) cognitive behavioral model of medically unexplained symptoms,
using the case example of inflammatory bowel disease. By doing so, this study adds
depth to the body of literature on CBT model of MUS, and fills a critical gap by
demonstrating both the role of precipitating factors in the model, and that body vigilance
scale specifically may serve this function.
Research Question
It was hypothesized that in the current study, after controlling for the variance in
health-related quality of life explained by predisposing factors (gender, diagnosis,
neuroticism and alexithymia,) and perpetuating factors (chronicity, cyclical timeline,
consequences, personal control, treatment control, illness coherence, and emotional
representation), the precipitating factor body vigilance would account for significant
additional variance in health-related quality of life.
The results of the multiple regression analysis supported the research hypothesis.
The extent to which adults with inflammatory bowel disease (IBD) attended to internal
sensations and monitored for symptoms explained a significant portion of the variance in
symptom severity, even when controlled for sex, diagnosis, personality and illness
perceptions. The full model accounted for 47% of the variance in symptom severity as
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measured by the IBDQ and the addition of the precipitating factor, body vigilance
accounted for roughly 2.4% of the total variance. The strength of correlation between
body vigilance and symptom status was nearly twice that of previous research in irritable
bowel syndrome (IBS) (Keough et al., 2011). Although this relationship is consistent
with the CBT model of MUS, it does not necessarily indicate that the additional variance
explained by body vigilance is due to sensitization, and in fact some evidence suggests
the opposite process occurs.
Whereas measures of pain detection thresholds show sensitization to rectal pain
among patients with IBS, attenuated pain perception has been observed in patients with
IBD (Chang et al., 2000) suggesting important differences between IBS and IBD in the
etiology of pain, and potential fit of the CBT model of MUS. However the breadth of
symptoms and the impact of illness extend far beyond the experience of pain. For
example the IBDQ, the widely accepted measure of disease status in IBD used in the
current study, also assesses for fatigue, nausea, social and emotional consequences,
embarrassment, impairment in sexual functioning among the numerous areas that that the
disease impacts people. Each of these negative consequences could potentially contribute
to changes in body vigilance. Further analysis using structural equation modeling or
path analysis as well as longitudinal studies may add clarity to the nature of the
relationship of body vigilance to other variables in the CBT model of MUS.
Although personality variables showed significant correlations with illness
cognitions, body vigilance and with health related quality of life, when all variables were
entered in the regression equation, neither neuroticism nor any of the scales of
alexithymia individually explained significant portions of variance in health related
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quality of life. This is in contrast to previous research on MUS which showed
associations between neuroticism for instance, and harm avoidance (Cloninger, 1987),
increased experience of physical symptoms after an aversive stimulus (Petrie et al.,
2004), disproportionate attention to pain or fear (Matthews et al., 2003), and poorer
health related quality of life in general populations (Kressin et al., 2000) and in patients
with chronic health conditions (Patten, 2001). Likewise, alexithymia had previously been
shown to predict health related quality of life among adults with IBD (Verissimo et al.,
1998). In the current study, the association between both personality variables and health
related quality of life was non-significant, however, when predisposing variables were
entered together in a single block, the variance explained was significant. Likewise,
when all illness perceptions were entered in block two of the three step regression as
perpetuating factors, significant additional variance was explained. This supports the
organizational structure of the CBT model of MUS by showing that non-significant
predictors when applied in combination can explain significant variance.
Limitations
Although the current study provides support for the CBT model of MUS, it must
be interpreted in light of several limitations. An intended strength of this study was the
use of a population with IBD, a medical illness with a rigorous and definitive diagnostic
process to illustrate the role of body vigilance in the CBT model of MUS, thus
eliminating the confounds of purely psychogenic disorders such as conversion and
somatization. This was in keeping with a liberal definition of MUS (Swanson et al.,
2010). In selecting this sample population however, it was ensured that some degree of
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medical explanation was present which may account for some differences in the present
results and other studies of MUS populations.
Another limitation in the present study is the omission of some variables
suggested in the theory. The CBT model of MUS also leaves open the possibility for
classes of variables such as coping, which, if included in their entirety, would make the
survey prohibitively long. Wherever possible, redundancy in conceptually and
statistically related variables was eliminated, while maintaining the constructs identified
in the model (Deary et al., 2007). Although the cognitive model suggests an order of
influence and causal direction, since this study is a non-experimental, correlational
design, results cannot demonstrate causal relationships between variables.
Another potential limitation in this study lies in the sampling method. Since
participants were recruited from online support organizations, it is possible that the
sample over-represented younger and more technologically fluent people or that members
of the Crohn’s and Colitis Foundation of America (CCFA) would be overrepresented.
CCFA, however, is currently the most comprehensive source of national data on IBD
(Kalibjian, 2003); therefore an overrepresentation of members will be unlikely to
introduce any bias that would limit the validity of the results. Furthermore, IBD affects
primarily young adults (Loftus, Schoenfeld, & Sandborn, 2002), the same age groups that
would be expected to have the greatest access to online forums. Skew in age then, would
likely mirror the age distribution of IBD and would be unlikely to introduce bias.
The sample drawn in the current study was heavily weighted towards female
participants, and those with Crohn’s disease relative to ulcerative colitis. It does not
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appear that this influenced the results, which were in line with previous research that had
more balanced samples.
At first glance, the lack of racial diversity appears troubling; with over 93% of the
sample reporting race as Caucasian. IBD has traditionally been diagnosed at much higher
rates among people whose lineage points to Northern Europe, Scandinavia, and United
Kingdom (Loftus et al., 2002) so some skew towards Caucasian participants may be
expected. These differences in disease appearance seem to be waning over time however
as populations migrate and diagnostic screening improves (Basu, Lopez, Kulkarni, &
Sellin, 2005) Basu et al. (2005) note differential patterns of diagnosis according to race
with African American and White identified people being diagnosed with CD whereas
Mexican-Americans tended to be diagnosed with UC. The current sample had
insufficient numbers of African American and Mexican American participants for any
substantive analysis or race and diagnosis. Future studies would benefit from a more
diverse sample.
As with any self-report measures, the instruments used in this study are subject to
individual participants’ idiosyncratic interpretation and response biases. Responses
regarding specific illness identity may be assumed to be accurate since multiple imaging
including endoscopy and or colonoscopy with tissue biopsy is generally required for a
diagnosis of Crohn’s disease or ulcerative colitis (Kalibjian, 2003). Since these
diagnostic tests can only be performed by physicians qualified to diagnose either
condition, the danger of ambiguous or incorrect self-diagnosis is minimal. Social
desirability and potential embarrassment may influence self-report responses; however,

64

the anonymous nature of the tests and the stated purpose of advancing research that will
benefit those with IBD likely encouraged honest, non-biased answers.
Responses in this data collection showed evidence of both idiosyncratic
interpretation and also limitations in the instruments when applied to IBD. For instance,
several participants who had diagnoses of ulcerative colitis, had ileostomies or “jpouches” after surgical removal of the large intestine. For these participants, the
symptom profiles they experience are drastically different, with “flares,” pain, and the
sensation of urgency subsiding and chronic maintenance becoming more of a focal
concern. One participant commented: “I have a permanent ileostomy due to UC ...it has
resolved many of the negative quality of life issues of IBD.” Whether this participant
viewed continued care for the ileostomy as related to the IBD that necessitated the
surgery was unclear. Although the IBDQ is currently the best available instrument for
assessing subjective distress of IBD, some important facets of the disease experience are
omitted which may lead to under-reporting of severity.
Similarly, participant comments related to the BVS scale suggested that specific
wording related to “scanning” one’s body for symptoms was problematic. One
participant commented “I feel what I feel, I don’t ‘scan my body’ for it,” and another
wrote “I don’t ‘scan’ my body; symptoms are so strong that there is no need.” In
contrast, several participants commented about the importance of being “in tune” with
one’s body, particularly in light of absorption issues, which are common in IBD.
Idiosyncratic interpretation of “scanning” may have caused an under-reporting of
vigilance as several participants wrote that they were constantly aware, yet never
intentionally scanning their bodies. This also may lead to underreporting of symptoms.
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Several participants indicated comorbid medical diseases, which they believed to
be secondary to their IBD. Likewise, several participants indicated concurrent
psychological diagnoses including major depression, posttraumatic stress disorder and
unspecified eating disorders, which could cloud interpretation of these test results. In the
current study, the number of participants reporting comorbid medical and mental health
conditions was small; however, the feedback from these participants was valuable.
Relevance to the Field of Counseling Psychology
The likelihood of counseling psychologists encountering a client with a medically
unexplained symptom is high, particularly for those working in primary care settings, in
collaboration with medical providers in behavioral health and preventive medicine
settings or in practices organized as part of a patient-centered medical home. As the
instance rate of chronic conditions increases and the number of patients whose distress
exceeds medical explanation continues to grow, the importance of psychologists in
integrated care will likewise increase, particularly as chronic and complex health
conditions become increasingly more common and even normative.
Further, pressure by managed care organizations to employ empirically supported
treatments, and psychologists’ ethical duty to provide the best possible care makes
evident the need for research in this area. Cognitive behavioral therapy has produced the
most empirically validated treatments for the population with MUS, and the CBT model
of MUS is the predominant guiding theory for treatment. Evidence that increased body
vigilance is associated with greater MUS severity gives potentially useful insight to
interventions that could reduce subjective distress. Complementary alternative medicine
modalities such as prayer, guided imagery, meditation, relaxation, and yoga are becoming
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popular among patients and healthcare providers, and are gaining empirical support for
symptom management (Cotton et al., 2010; Gaylord et al., 2011).
Many counseling psychologists in general practice therefore are likely to
encounter a client with MUS, and will also likely be subject to pressure to use empirically
supported treatment such as CBT in their work. In that sense, the findings from this
study will be directly applicable to counseling psychology practice. Perhaps more
importantly, this study highlights the dynamic nature of stressors of chronic illness, and
the importance of including measures of precipitating factors such as body vigilance,
which can account for differences in sensitivity and reactivity to symptoms when
assessing overall distress.
Implications for Education
Medically unexplained symptoms are notoriously dysregulating to the individuals
who experience them, and difficult for health care providers to treat effectively. The
present study shows that the addition of a the body vigilance scale, a psychometric
measure of sensitization to the CBT model of MUS explains significant additional
variance in health related quality of life, a widely accepted benchmark for both
psychological and physical health among people with IBD. The full model accounted for
nearly half of the variance observed. This is strong support of the role of psychological
theory in describing, and predicting well-being in this population and further support of
the role of psychologists in contributing to effective and comprehensive health care. It
will be increasingly important for counseling psychologists to be fluent in a wide range of
health functioning including MUS, and to be able to communicate this information to
other health care providers and patients.
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Central to the education of counseling psychologists is training in critical
evaluation of research, and translation of findings into treatment recommendations that
are grounded in empirical support, personalized to the needs of the patient. This often
involves adapting previously established theories to novel population groups or settings.
The present study shows that although the CBT model of MUS is useful in describing
categories of predictors to explain variance in health related quality of life among adults
with IBD, differences still exists between this population and other medical populations
that have been studied through this model.
Future Research
By using the sample population of adults with IBD, it was possible to eliminate
purely psychogenic sources of MUS. It is also possible that in doing this, some degree
of medical explanation was essentially guaranteed which may separate IBD from other
populations studied through the lens of the CBT model of MUS. This difference may
also be related to variable definitions of MUS as noted in chapter 2. As research in MUS
continues, it will be helpful to make explicit the particular definition of MUS being used
to ease application of results across studies.
In response to confounds identified in the previous sections, researchers might
screen for and exclude comorbid conditions which might introduce bias. Doing so
however could systematically exclude the more severe cases, and those who may
potentially benefit the most from research. Several participants in the current study
included comments indicating severe emotional and financial strain as a result of IBD
which in turn may in turn increase the susceptibility to distress through strained
relationships, insecure housing or access to healthcare. This highlights the importance of
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including a broad spectrum of participants, and whenever possible, expanding the ways in
which we in the field of counseling psychology assess and treat illness distress.
Among the important findings of the current study is the evidence that the CBT
model of MUS can be used to organize influences of subjective distress related to disease
among people with IBD, a population that has received proportionally little attention.
Future research both in MUS and in IBD would benefit from more diverse samples,
particularly among racial and ethnic minorities as well as disease specific measures.
Comments from participants in the current study highlight the particular need for
customization of existing measures to particular populations and “ground-up” measures.
A full report of the psychometric properties of the assessment tools used is outside the
scope of this study, but would be useful in directing future research.
Additionally, the CBT model of MUS implies the potential of a recursive model
in which precipitating factors may be a method of feedback in a more dynamic system
than this study assumed. More in-depth statistical analysis using structural equation
modeling may shed light on possible mediation or moderation effects.
Conclusion
Overall, the hypothesis that body vigilance would predict health related quality of
life and serve as a precipitating factor of illness-related distress as suggested by Deary et
al.’s (2007) cognitive behavioral model of medically unexplained symptoms was
supported by the analyses. Body vigilance was found to significantly increase the
variance explained by the set of variables derived from the theory. In addition, the threestep regression showed support for the theoretical structure of the model by showing that
variables which individually were non-significant, when used in combination explained
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significant variance. This study provided additional support for the use of inflammatory
bowel disease as a model population to study illness distress which exceeds medical
explanation. Significant correlations between both personality variables and illness
cognitions, and illness distress which were previously documented were observed in this
study. Neither measure of personality accounted for significant variance in symptom
severity, indicating that dimensions of personality do not explain to MUS among people
with IBD. Among illness cognitions, belief in the chronic recurrence, severe
consequences and personal control all explain significant variance.
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Appendix A
Electronic Solicitation and Informed Consent
Health-Related Quality of Life in Patients with Inflammatory Bowel Disease.
People with a diagnosis of Crohn’s Disease or Ulcerative Colitis and who are 18 years
of age or older are invited to participate in a study examining health related quality of
life in inflammatory bowel disease. By answering a series of brief questionnaires, you
will be contributing to research efforts in understanding how to prevent unnecessary
distress and improve subjective quality of life for people living with IBD. In addition
to our sincere gratitude, eligible participants will have the option of a $3 Amazon.com
credit, or a $3 donation to the CCFA on your behalf.
The present study is being conducted as part of a doctoral dissertation in counseling
psychology at the University of Memphis. The person in charge of this study is Aron
Katz, under the supervision of Douglas Strohmer, Ph.D., chair of the department of
Counseling Education Psychology and Research. The purpose of this study is to
expand our understanding of the factors that contribute to health-related quality of life
in medically complex illnesses by applying the cognitive behavioral model of medically
unexplained and under-explained symptoms to people with IBD. Those interested in
participating are encouraged to go to: https://www.surveymonkey.com/s/IBDstudy to
take the survey online. Questions about the research project may be directed to
amkatz@memphis.edu and will be answered as quickly as possible.
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Consent to Participate in a Research Study
WHY ARE YOU BEING INVITED TO TAKE PART IN THIS RESEARCH?
You are being invited to take part in a research study about the factors contributing to symptoms of
Inflammatory Bowel Disease. If you volunteer to take part in this study, you will be one of about 155
people to do so nationally.

WHO IS DOING THE STUDY?
The person in charge of this study is Aron Katz of University of Memphis Department of Counseling
Psychology. He is being guided in this research by Douglas Strohmer, Ph.D. There may be other people
on the research team assisting at different times during the study.
WHAT IS THE PURPOSE OF THIS STUDY?
The purpose of this study is to test the influence of new variables in the cognitive behavioral model of
medically unexplained and under-explained symptoms. This is the prevalent model of psychological
treatment and complementary care of people with unexplained or under-explained symptoms. By doing
this study, we hope to clarify factors contributing to illness related distress in an attempt to improve
patient care and reduce illness related distress in medically unexplained symptoms in general and IBD in
particular.
ARE THERE REASONS WHY YOU SHOULD NOT TAKE PART IN THIS STUDY?
People under the age of 18, or over the age of 70 are not eligible for this study, and those who believe
they have Crohn’s disease or ulcerative colitis but have not been diagnosed by a gastroenterologist
should not participate.
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT LAST?
The research procedures will be conducted electronically so you, as the participant may take the
following survey at a time and location convenient to you. The total amount of time required to take the
full survey should be between 30 and 45 minutes.
WHAT WILL YOU BE ASKED TO DO?
You will be asked a series of questions with instructions at the top of every page. Please read the
instructions and answer honestly.
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS?
To the best of our knowledge, the things you will be doing have no more risk of harm than you would
experience in everyday life.
WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY?
Your willingness to take part in this study may, in the future, help health care providers better understand
and treat symptoms of medically unexplained and under-explained symptoms including those associated
with inflammatory bowel disease.
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DO YOU HAVE TO TAKE PART IN THE STUDY?
If you decide to take part in the study, it should be because you really want to volunteer. You will not
lose any benefits or rights you would normally have if you choose not to volunteer. You can stop at any
time during the study and still keep the benefits and rights you had before volunteering.
IF YOU DON’T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER CHOICES?
If you do not want to be in the study, there are no other choices except not to take part in the study.

WHAT WILL IT COST YOU TO PARTICIPATE?
There are no costs associated with taking part in the study.
WILL YOU RECEIVE ANY REWARDS FOR TAKING PART IN THIS STUDY?
You will receive a $3 credit to Amazon.com or comparable service for taking part in this study.
WHO WILL SEE THE INFORMATION THAT YOU GIVE?
We will make every effort to keep private all research records that identify you to the extent allowed by
law. Your information will be combined with information from other people taking part in the study.
When we write about the study to share it with other researchers, we will write about the combined
information we have gathered. You will not be personally identified in these written materials. We may
publish the results of this study; however, we will keep your name and other identifying information
private.
We will make every effort to prevent anyone who is not on the research team from knowing that you
gave us information, or what that information is. Electronic data will be stored on password protected
media with identifying information removed.
CAN YOUR TAKING PART IN THE STUDY END EARLY?
If you decide to take part in the study you still have the right to decide at any time that you no longer
want to continue. You will not be treated differently if you decide to stop taking part in the study.
WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, CONCERNS, OR COMPLAINTS?
Before you decide whether to accept this invitation to take part in the study, please ask any questions that
might come to mind now. Later, if you have questions, suggestions, concerns, or complaints about the
study, you can contact the investigator, Aron Katz at amkatz@memphis.edu. If you have any questions
about your rights as a volunteer in this research, contact the Institutional Review Board staff at the
University of Memphis at 901-678-3074. We will give you a signed copy of this consent form to take
with you.
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Appendix B
Demographic Questionnaire
Please complete the following questions about yourself. This information is private and
will remain confidential. If you have any comments, you are welcome to write them in
the box provided and they will be taken into consideration. Please mark the appropriate
field to answer the questions below:
1.

I am: Male / Female

2.

My age is:______.

3.

I am (mark those that apply)
Caucasian/White
African American
Asian/Pacific Islander
Hispanic/Latino
Native American/Alaskan Native
Other: __________________________

4.

Highest level of education completed:
High School / no college
High School / some college
Associates degree
Bachelor’s degree
Master’s degree
Doctorate or professional degree

5.

I have been diagnosed by a gastroenterologist with:
Crohn’s Disease
Ulcerative Colitis
Neither

6.

Approximate date of diagnosis

7.

Current medications:

8.

In the past twelve (12) months, how many flares have you experienced?

9.

In the past two (2) years, how many flares have you experienced?

10. In the past year, how many times have you been admitted to the hospital due to your
IBD?
11. How many surgeries have you had related to your IBD?
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Appendix C
Toronto Alexithymia Scale (TAL-20)

Please rate how much you agree with the following statements using the scale provided.
1. I am often confused about what emotion I am feeling
Strongly Disagree
1

Strongly Agree
2

3

4

5

2. It is difficult for me to find the right words for my feelings
Strongly Disagree
1

Strongly Agree
2

3

4

5

3. I have physical sensations that even doctors do not understand.
Strongly Disagree
1

Strongly Agree
2

3

4

5

4. I am able to describe my feelings easily.
Strongly Disagree
1

Strongly Agree
2

3

4

5

5. I prefer to analyze problems rather than just describe them.
Strongly Disagree
1

Strongly Agree
2

3

4

5

6. When I am upset, I do not know if I am sad, frightened or angry.
Strongly Disagree
1

Strongly Agree
2

3

4

5

7. I am often puzzled by sensations in my body.
Strongly Disagree
1

Strongly Agree
2

3

4

5

8. I prefer to just let things happen rather than to understand why they turned out
that way.
Strongly Disagree
1

Strongly Agree
2

3

4

5

9. I have feeling that I cannot quite identify
Strongly Disagree
1

Strongly Agree
2

3

4

5

10. Being in touch with emotions is essential.
Strongly Disagree
1

Strongly Agree
2

3

4

5

11. I find it hard to describe how I feel about people.
Strongly Disagree
1

Strongly Agree
2

3
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4

5

12. People tell me to describe my feelings more.
Strongly Disagree
1

Strongly Agree
2

3

4

5

13. I do not know what is going on inside me.
Strongly Disagree
1

Strongly Agree
2

3

4

5

3

4

5

14. I often do not know why I am angry.
Strongly Disagree
1

Strongly Agree
2

15. I prefer talking to people about their daily activities rather than their feelings.
Strongly Disagree
1

Strongly Agree
2

3

4

5

16. I prefer to watch "light" entertainment shows rather than psychological dramas.
Strongly Disagree
1

Strongly Agree
2

3

4

5

17. It is difficult for me to reveal my innermost feelings, even to close friends.
Strongly Disagree
1

Strongly Agree
2

3

4

5

18. I can feel close to someone, even in moments of silence.
Strongly Disagree
1

Strongly Agree
2

3

4

5

19. I find examination of my feelings useful in solving personal problems.
Strongly Disagree
1

Strongly Agree
2

3

4

5

20. Looking for hidden meanings in movies or plays distracts from their enjoyment.
Strongly Disagree
1

Strongly Agree
2

3
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4

5

Difficulty Identifying Feelings: Sum of responses for items:
1
_____
3
_____
6
_____
7
_____
Total _____
9
_____
13 _____
14 _____
Difficulty Describing Feelings: Sum of responses for items:
2
_____
4* _____
11 _____
Total _____
12 _____
17 _____
Externally Oriented Thinking: Sum of responses for items:
5* _____
8
_____
10* _____
15 _____
16 _____
Total _____
18* _____
19* _____
20 _____

* Denotes an item which is reverse scored.
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Appendix D
Illness Perception Questionnaire-Revised

YOUR VIEWS ABOUT YOUR IBD
Listed below are a number of symptoms that you may or may not have experienced
since your IBD. Please indicate by circling Yes or No, whether you have experienced
any of these symptoms since your IBD, and whether you believe that these symptoms
are related to your IBD.

I have experienced this
symptom since my IBD
Pain
Sore Throat
Nausea
Breathlessness
Weight Loss
Fatigue
Stiff Joints
Sore Eyes
Wheeziness
Headaches
Upset Stomach
Sleep Difficulties
Dizziness
Loss of Strength

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
No ____________________ Yes
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This symptom is
related to my IBD
No
No
No
No
No
No
No
No
No
No
No
No
No
No

We are interested in your own personal views of how you now see your current IBD.
Please indicate how much you agree or disagree with the following statements about
your IBD by ticking the appropriate box.

Views about your IBD

Strongly
Disagree

Disagree

My IBD will last a short
time
My IBD is likely to be
permanent rather than
Temporary
My IBD will last for a long
time
This IBD will pass quickly
I expect to have this IBD
for the rest of my life
My IBD is a serious
condition
My IBD has major
consequences on my life
My IBD does not have
much effect on my life
My IBD strongly affects the
way others see me
My IBD has serious
financial consequences
My IBD causes difficulties
for those who are
close to me
There is a lot which I can
do to control my
symptoms

106

Neither
Agree
Nor
Disagree

Agree

Strongly
Agree

What I do can determine
whether my IBD gets
better or worse
The course of my IBD
depends on me
Nothing I do will affect my
IBD
I have the power to
influence my IBD
My actions will have no
affect on the outcome
of my IBD
My IBD will improve in
time
There is very little that can
be done to
improve my IBD
My treatment will be
effective in curing my
IBD
The negative effects of my
IBD can be
prevented (avoided) by my
treatment
My treatment can control
my IBD
There is nothing which can
help my condition
The symptoms of my
condition are puzzling to
me
My IBD is a mystery to me
I don’t understand my IBD

My IBD doesn’t make any
sense to me
I have a clear picture of
understanding of my
condition
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The symptoms of my IBD
change a great deal from
day to day

My symptoms come and go
in cycles

My IBD is very
unpredictable

I go through cycles in
which my IBD gets
better and worse.

I get depressed when I
think about my IBD

When I think about my
IBD I get upset

My IBD makes me feel
angry

My IBD does not worry me

Having this IBD makes me
feel anxious

My IBD makes me feel
afraid
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CAUSES OF MY IBD
We are interested in what you consider may have been the cause of your IBD. As people are
very different,
there is no correct answer for this question. We are most interested in your own views about
the factors that
caused your IBD rather than what others including doctors or family may have suggested to
you. Below is a
list of possible causes for your IBD. Please indicate how much you agree or disagree that they
were causes for
you by ticking the appropriate box.

Possible Causes

Strongly
Disagree

Disagree

Stress or worry
Hereditary - it runs
in my family
A Germ or virus
Diet or eating habits
Chance or bad luck
Poor medical care in
my past
Pollution in the
environment
My own behavior
My mental attitude
e.g. thinking about
life negatively
Family problems or
worries
Overwork
My emotional state
e.g. feeling down,
lonely, anxious,
empty
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Neither
Agree Nor
Disagree

Agree

Strongly
Agree

Ageing
Alcohol
Smoking
Accident or injury
My personality
Altered immunity

In the table below, please list in rank-order the three most important factors that you now
believe caused YOUR IBD. You may use any of the items from the box above, or you may
have additional ideas of your own.
The most important causes for me:
1. _______________________________________
2. _______________________________________
3. _______________________________________
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Appendix E
Body Vigilance Scale (BVS)
Instructions: This measure is designed to index how sensitive you are to internal bodily
sensations such as heart palpitations or dizziness. Fill it out according to how you have
felt for the past week.
1. I am the kind of person who pays close attention to internal bodily sensations.
0
1
2
3
4
5
6
7
8
9
10
Not Like Me
Moderately Like Me
Extremely Like Me

2. I am very sensitive to changes in my internal bodily sensations
0
1
2
3
4
5
6
7
8
9
10
Not Like Me
Moderately Like Me
Extremely Like Me
3. On average, how much time do you spend each day “scanning your body for
sensations (e.g. sweating, heart palpitations, dizziness)?
0
1
2
3
4
5
6
7
8
9
10
Not Like Me
Moderately Like Me
Extremely Like Me

4. Rate how much attention you pay to each of the following sensations using this
scale:
0
1
2
3
4
5
6
7
8
9
10

None

Slight

Moderate

Substantial

1. Heart palpitations
2. Chest pain/discomfort
3. Numbness
4. Tingling
5. Short of breath / smothering
6. Faintness
7. Vision changes
8. Feelings of unreality
9. Feeling detached from self
10. Dizziness
11. Hot flash
12. Sweating/clammy hands
13. Stomach upset
14. Nausea
15. Choking/throat closing
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Extreme

